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ABSTRACT 
Cancer stem cells (CSCs) are defined as a small population of tumor initiating cells that 
are responsible for the initiation, development, progression, and recurrence of cancer. 
The chemo and radiation resistance of CSCs remains one of the major obstacles in 
conventional anti-cancer therapies. One of the reasons that conventional 
chemotherapeutics are not effective in targeting CSCs is that CSCs are usually in a non-
proliferative or dormant state. In this perspective, targeting CSCs by inducing its 
proliferation and differentiation and simultaneously applying chemotherapeutics may be 
an alternative approach. The current study investigates the effect of prolactin (PRL), a 
hormone intimately involved in mammary gland development, combined with cisplatin in 
targeting breast CSCs. We found that mammary gland CSCs treated with PRL undergo 
symmetric cell division with diminished ability to form tumorspheres. Moreover, the 
PRL and cisplatin combination treatment significantly inhibited secondary tumorsphere 
formation as compared to cisplatin alone, suggesting that PRL sensitized mammary gland 
CSCs to cisplatin. The IC50 value of cisplatin was cut by more than half with the addition 
of PRL in secondary tumorspheres formation assay. The effects of this combinational 
approach were further confirmed through tumor allograft growth in mice.  The inhibitory 
effect was likely through the inhibition of the PI3K/AKT pathway. Furthermore, PRL and 
cisplatin combination treatment of mammary tumors in neu transgenic mice significantly 
delayed tumor growth and reduced tumorigenicity. Taken together, this study provided 
evidence that addition of PRL to conventional chemotherapy (cisplatin) may be an 
effective method to target breast CSCs.  
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CHAPTER ONE 
INTRODUCTION 
 
Cancer 
According to the CDC, cancer is the second leading cause of death after heart disease, 
causing over a half million deaths in 2011 (CDC 2013). Cancer is defined as a group of 
diseases that are characterized by the uncontrollable growth and spread of abnormal cells. 
Normal cells are under strict control of proliferation, division and death in an orderly 
manner. In contrast, cancer cells are immortal and metastasize to other parts of the body 
through the bloodstreams and lymphatic systems.  
Currently, the exact cause of cancer remains unknown. However, we understand that 
dysregulation of genes controlling cell growth, division and death may cause cancer. 
Genetic damages to DNA and genes may cause cellular transformation, thus inducing 
early carcinogenesis. By definition, a proto-oncogene is a normal gene, but may induce 
cellular transformation after genetic damage. Oncogene is a gene that has already been 
genetically damage and its translated protein is capable of inducing cellular 
transformation. In contrast, tumor suppressor genes are genes that slow down cell 
division or cause cell death.  
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Hanahan and Weinberg proposed the Hallmark of Cancer in 2000 (Hanahan and 
Weinberg 2000) in which they proposed that most cancers acquire six alterations during 
the cell transformation process, including 1) sustaining proliferative signaling, 2) evading 
growth suppressors, 3) resisting cell death, 4) enabling replicative immortality, 5) 
inducing angiogenesis, and 6) activating invasion and metastasis. Over the past decade, 
Hanahan and Weinberg proposed emerging hallmarks including deregulating cellular 
energetics, avoiding immune destruction, genomic instability and mutations and tumor-
promoting inflammation (Hanahan and Weinberg 2011). Furthermore, interaction of 
different distinct cell types including cancer stem cells, cancer-associated fibroblasts, 
immune cells and stromal cells constitute the complexity of the tumor microenvironment, 
which remains to be an important aspect in cancer biology for further investigation.  
Depending on the type of cancer, major types of treatment involve surgery, radiation 
therapy, chemotherapy, immunotherapy and hormone therapy. The recommendation of 
therapy considers the type of cancer, location of cancer, stages and status of the cancer 
and the health condition of the patient. Often the first line of treatment for many solid 
tumors is surgery which is very effective by removing all the cancerous cells at early 
stages. Radiation therapy can also kill cancer cells directly by using high energy beams. 
Chemotherapy kills cancer cells by targeting cell division. Immunotherapies are 
therapeutics designed for stimulating the bodies owns defenses, thus killing cancer cells. 
Hormone therapies are drugs that are designed to prevent cell growth from receiving 
specific signals for their proliferation and survival. Other emerging therapeutic 
approaches include using specific inhibitors by targeting specific protein and cellular 
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processes that are primarily limited to cancer cells, either extracellularly or intracellularly; 
or by using vaccines to stimulate the body’s defense against cancer or prevent cancer 
formation.  
However, it is important to note that surgery, radiation and chemo-therapy may not 
eliminate all the cancer cells, as surgery is such a macroscopic procedure, residual cells 
may cause recurrence of cancer. Resistance of radiation, chemo-therapy, hormone and 
immunotherapies may be developed in cancer cells, causing tumors with poor or no 
response to drug treatment thus making resistance one of the major obstacles in cancer 
treatments. Taken together, conventional therapeutic approaches may not be effective in 
certain scenarios necessitating the development of alternative approaches.  
Breast cancer 
According to the American Cancer Society, breast cancer is the second leading cause of 
death of women diagnosed with cancer, exceeded only by lung cancer. In 2013, the 
American Cancer Society estimates about 232,340 (29% of all cancer types) of women 
will be diagnosed with breast cancer, and 39,620 (14% of all cancer types) will die from 
breast cancer this year (American-Cancer-Society 2013). The chance of dying from 
breast cancer for a woman is about 3%. Though the incidence rate had been increasing 
from 1980-2000s, the rate has been decreasing since 2002; this is thought to be due to the 
decline in the use of hormone therapy after menopause. Death rates from breast cancer 
have been declining since about 1989 and larger decreases were observed in women 
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younger than the age of 50 (American-Cancer-Society 2013). This decrease is thought to 
be linked with the efforts of early detection through screening and awareness along with 
improvement of treatments.  
Breast cancer is a heterogeneous disease. Risk factors include but are not limited to: 
advanced age at the first full term pregnancy, family history of breast cancer, higher 
socioeconomic status, earlier age of menstrual cycle, prolonged nulliparity and history of 
benign breast disease (Russo and Russo 2004). Based on histopathological classification, 
breast cancer can be generally categorized in two categories, in situ carcinoma and 
invasive carcinoma (Malhotra, Zhao et al. 2010).  
In situ carcinoma 
In situ carcinoma is defined as the absence of invasive cancer cells penetrating the 
basement membrane in a neoplastic condition (Ernster and Barclay 1997). In breast 
cancer, the major form of in situ carcinoma is ductal carcinoma in situ (DCIS). DCIS is 
an early form of breast cancer in which the epithelial cells proliferate in the lining of the 
mammary duct that haven’t penetrated through the basement membrane and invaded the 
nearby tissues (Ernster and Barclay 1997).  However, if left untreated, DCIS may 
progress to invasive cancer.  DCIS is sub-categorized into low grade, intermediate grade 
and high grade depending on the cell morphology, architecture, and the presence of 
necrosis. Low grade DCIS consists of monomorphic, evenly spaced cells with rounded 
center place nuclei, infrequent mitosis and necrosis is rarely observed. High grade DCIS 
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consists of pleomorphic, irregular spaced cells, large nuclei that vary in size and nuclear 
content, and frequent mitosis. Intermediate DCIS lies between the characteristics of low 
and high grade DCIS, it consists of larger nuclei than DCIS and moderate pleomorphism 
of cells (2005). Atypical hyperplasia is thought to be a precursor lesion of low grade 
DCIS and may subsequently develop into low grade invasive cancer. High grade DCIS 
does not have obvious precursor lesions but has a higher risk progressing to high grade 
invasive disease (Barnes, Ooi et al. 2012). Though the development of DCIS is poorly 
understood, studies have suggested that low/intermediate grade DCIS may develop 
differently from high grade DCIS. Low grade DCIS often shows a loss of 16q 
chromosome, whereas high grade DCIS often shows a gain of 17q (Hwang, DeVries et al. 
2004).  
Risk factors of developing DCIS include family history of breast cancer, nulliparity 
(pregnancy less than 20 weeks), BRCA1 and BRCA2 mutation (Claus, Stowe et al. 2001; 
Claus, Petruzella et al. 2005). DCIS was rarely detected until the introduction of 
mammography. Mammography is the use of low energy x-rays to examine the breast 
malignancy. The rate of DCIS detection by mammography has been steadily increasing 
since the 1980s (Ernster and Barclay 1997). Most cases of DCIS are detected at screening 
while asymptomatic. DCIS that is detected with clinical signs is more likely to be 
preinvasive (Oct 2009).  
Patients who are diagnosed with DCIS at mammography screening need further 
confirmation by biopsy (Barnes, Ooi et al. 2012). Most DCIS treatment involves primary 
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surgery when the lesion is still localized. If there are no signs of extensive DCIS, an 
excision option will be available including microdochectomy (removal of the 
symptomatic duct(s)), or total duct excision (Barnes, Ooi et al. 2012). If the area of DCIS 
is extensive, wide local excision or mastectomy will be suggested. Adjuvant therapy 
including radiotherapy and tamoxifen may be offered to prevent recurrence depending on 
the extensiveness of DCIS (Barnes, Ooi et al. 2012). 
Invasive carcinoma 
Invasive carcinomas are a heterogeneous group of tumors differentiated into histological 
subtypes including invasive ductal carcinoma (IDC) (50-80%), invasive lobular 
carcinoma (ILC) (5-15%), mucinous (<5%), tubular (1-6%) and medullary carcinomas 
(1-7%) (Weigelt, Horlings et al. 2008).  The majority of invasive carcinomas in breast 
cancer are diagnosed as invasive ductal carcinoma (IDC), sometimes known as 
infiltrating ductal carcinoma.  
Invasive ductal carcinoma can be further sub-categorized into well differentiated (grade 
1), moderately differentiated (grade 2) and poorly differentiated (grade 3) depending on 
the nuclear pleomorphism, glandular and tubule formation and mitotic index (Lester, 
Bose et al. 2009). Unlike DCIS and ALH/LCIS, biological markers (ER, PR and 
HER2/neu) are well accepted in IDC and used as guidance for treatment approach (Harris, 
Fritsche et al. 2007).  Immunohistochemistry staining revealed that the majority of IDC 
grade 1 are ER+, with approximately 5% are HER2+. Clinical studies revealed that 
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patients with grade 1 IDC expect the most optimistic treatment outcome. The overall 10-
year survival rate is up to 96% (Blamey, Ellis et al. 2007). IDC samples that are 
diagnosed as grade 3 expect poor clinical outcome with the 10-year survival rate ranging 
between 38-55% (Blamey, Ellis et al. 2007).  
Treatment options of IDC depend on the size of the tumor, molecular and lymph node 
status. Typically a tumor with a size less than 4cm would be excised surgically along 
with the lymph nodes in the auxiliary area. The stage of the tumor is determined after this 
first surgery along with other previous medical observations. Adjuvant therapy including 
chemo, radiation, hormonal (such as Tamoxifen) and/or targeted therapy (such as 
Herceptin) may be applied for the prevention of recurrence. Further surgery for complete 
tumor removal will be determined based on individual cases. A patient with a tumor that 
is larger than 4cm would receive a recommendation for a mastectomy as the tumor size 
has exceeded the criteria of lumpectomy. Follow up treatment options would be offered 
to individual patients based on multiple factors such as the stage of cancer, age, 
individual’s medical history, etc.  
Molecular subtypes of breast cancer and targeted treatment 
Though the conventional breast classification based on histopathology has its prognostic 
value, molecular classification provides another perspective of breast cancer in terms of 
response prediction and newer targets. Currently there are six molecular subtypes in 
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breast cancer, i.e. normal breast-like, luminal A, luminal B, HER2+, basal like and 
claudin low.  
Normal Breast-like 
Normal breast-like tumors resembles normal breast tissue samples but with relatively 
high gene expression of adipose cells and non-epithelial cell types, low gene expression 
of luminal epithelial cells types (Perou, Sorlie et al. 2000).  
Luminal A/B 
Approximately 40% of breast cancers are classified as luminal A breast cancer (Malhotra, 
Zhao et al. 2010). Luminal A breast cancer is characterized by ER+/PR+/HER2-. 
Compared to Luminal subtype B, luminal A breast cancer is sensitive to tamoxifen and 
often associated with better clinical outcome and prognosis (van 't Veer, Dai et al. 2002).  
Luminal B breast cancer comprises approximately 20% of breast cancers (Malhotra, Zhao 
et al. 2010).  ER+, luminal B breast cancer is often found to be associated with higher 
histological grade, greater genomic instability, poorer prognosis and is tamoxifen 
resistant when compared to Luminal subtype A (Cui, Schiff et al. 2005; Viale, Regan et 
al. 2007; Cheang, Chia et al. 2009; Park, Park et al. 2012).  Studies have also indicated 
that there is 7-10% probability luminal B breast tumors are also HER2+ (Cheang, Chia et 
al. 2009).  
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In luminal type A/B breast cancer, estrogen signaling plays an important role in the ER+ 
breast cancer. Binding of estrogen causes dimerization of ER, facilitates recruitment of 
co-activator complexes, thus activation gene transcription that promotes cell proliferation, 
survival, angiogenesis and tumor metastasis. Selective ER modulators (SERMs) and 
Fulvestrant are two common ER blockers used clinically.  
Tamoxifen, a member in the SERM family, is the first line agent for endocrine therapy 
and also is used in adjuvant settings for all stages of ER+ breast cancer. 4-
hydroxytamoxifen (4-OHT) is the active metabolite of Tamoxifen, it binds to ER and 
blocks co-activator recruitment and recruits co-repressor to inhibit transcription of 
estrogen response genes (Sengupta and Jordan 2008). Tamoxifen has been shown to be 
effective in adjuvant settings. Administration of Tamoxifen for 5 years as adjuvant 
therapy significantly reduced cancer recurrence and mortality (Early Breast Cancer 
Trialists' Collaborative 2005). Tamoxifen has also been shown to be effective in breast 
cancer prevention, reducing breast cancer incidence by approximately 50% (Fisher, 
Costantino et al. 2005).  
Fulvestrant has been approved as a second line agent in endocrine therapy for ER+ breast 
cancer. Fulvestrant competitively binds to ER with high affinity and induces a 
conformational change of ER that leads to degradation of the ER protein (Johnston and 
Cheung 2010). Fulvestrant is used for treating postmenopausal women with ER+ breast 
cancer that has metastasized after treatment with other anti-estrogen agents.  
10 
 
 
HER2+ 
Human epidermal growth factor receptor 2 (HER2)-positive breast cancer comprises 
approximately 10-15% of breast cancer. HER2 is a transmembrane receptor with tyrosine 
kinase activity. Though there is little known about the ligand of HER2, HER2 is involved 
in regulating cell growth, survival and differentiation through the PI3K/Akt and MAPK 
pathway (Yarden and Sliwkowski 2001). Overexpression of HER2 results in constitutive 
active signaling of the downstream pathway. Studies have shown that in HER2+ tumors, 
HER2 is always in its active conformation and ready to interact with other HER members 
(HER1, HER3 and HER4) (Graus-Porta, Beerli et al. 1997). HER2+ breast cancer is 
often associated with high recurrence rate and poor prognosis (Tan and Yu 2007; Ross, 
Slodkowska et al. 2009).  
HER2+ tumor is characterized by overexpression of HER2. HER2+ breast cancer occurs 
in about 20% of breast cancer patients and is associated with aggressiveness. Currently 
the two approved agents for treating HER2+ tumors are Herceptin and Lapatinib.  
Herceptin is currently the only approved agent for early stage HER2+ breast cancer. 
Though the exact mechanism of its anti-tumor effect is not well understood, it is thought 
to be mediated through binding to the extracellular domain of HER2 receptor, thus 
inhibiting ligand-independent HER2 receptor dimerization, downstream signaling 
pathway and inducing apoptosis (Baselga, Albanell et al. 2001; Molina, Codony-Servat et 
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al. 2001; Spector and Blackwell 2009). In the adjuvant setting, Herceptin is 
recommended to use as a monotherapy after the completion of chemotherapy, or in 
combination with paclitaxel after completion of doxorubicin/cyclophosphamide, or in 
combination with carboplatin and docetaxel (2011; Goldhirsch, Wood et al. 2011). Meta-
analysis that includes six clinical trials demonstrated that combination of Herceptin with 
adjuvant chemotherapy prolongs disease-free survival rate when compared to chemo 
alone (Yin, Jiang et al. 2011). Clinical trials have also shown that the addition of 
Herceptin to neoadjuvant chemotherapy significantly improves pathological complete 
response rates and event-free survival in patients with locally advanced stage or early 
stage breast cancer (Buzdar, Ibrahim et al. 2005; Gianni, Eiermann et al. 2010).  
Other than Herceptin, Lapatinib is the only drug approved for patients with HER2 breast 
cancer. Lapatinib is a tyrosine kinase inhibitor, targeting intracellular tyrosine kinase 
activity of both HER1 and HER2, thus inhibiting downstream pathways such as MAPK 
and PI3K (Spector, Xia et al. 2005; Konecny, Pegram et al. 2006). Preclinical studies 
have suggested that Lapatinib may inhibit proliferation of HER2+ breast cancer cells that 
were Herceptin resistance (Xia, Liu et al. 2004). When combined with capecitabine 
(prodrug that converts into 5-fluorouracil), Lapatinib significantly increased response rate 
when compared to Lapatinib alone or capecitabine alone (Geyer, Forster et al. 2006; 
Cameron, Casey et al. 2008). The side effect of Herceptin (heart failure) is also reduced 
when combining Herceptin and Lapatinib treatment (Perez, Koehler et al. 2008).  
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Basal like 
Basal-like breast cancer comprises approximately 15-20% of breast cancers. Basal-like 
breast cancer expresses genes of basal/myoepithelial cells. Furthermore, basal-like 
tumors underexpress ER, ER expressive genes, and HER2 (Yehiely, Moyano et al. 2006). 
Basal-like tumors are often associated with young patient age, high histological grade, 
poor clinical outcomes, poor prognosis, poor survival rate, distant metastasis and high 
mortality rate (van de Rijn, Perou et al. 2002; Banerjee, Reis-Filho et al. 2006; Fulford, 
Reis-Filho et al. 2007). Interestingly, tumors with BRCA1 mutation are frequently found 
to be basal-like. Tumors arising from BRCA1 mutation carriers remarkably resemble 
morphology and transcriptome of basal-like breast cancer (Turner and Reis-Filho 2006). 
It is important to note that although there are similarities between basal-like and triple 
negative tumors (ER-/PR-/HER2-), the two groups do not completely overlap. Reports 
have shown that 15% to 45% of basal-like breast cancers express one of the three 
markers (Sorlie, Perou et al. 2001; Nielsen, Hsu et al. 2004; Calza, Hall et al. 2006).  
Triple negative breast cancer (TNBC) is defined as ER-, PR- and HER2-, therefore 
therapeutics targeting ER (such as Tamoxifen), HER2 (such as Herceptin) would be 
ineffective in treating TNBC. Standard treatment of early stages of TNBC remains to be 
administrating chemotherapeutic agents in a dense dose or metronomic schedule (Mehta 
2008). Though TNBC often results in poor prognosis, recent clinical trials have shed light 
upon treatment. Recent reports have revealed that TNBCs exhibit higher 
chemosensitivity to doxorubicin (anthracycline) or doxorubicin/cyclophosphamide 
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(taxane)-based chemo when compared to luminal/ER+ tumors in the neoadjuvant setting 
(Carey, Dees et al. 2007). Response rates of the treatment are reported to be 85% for 
TNBC, 70% for HER2+ and 47% for ER+. It is important to note that despite the 
increased chemosensitivity, patients with TNBC tumors and HER2+ tumors continued to 
have the poorest disease-free survival rate and overall survival rate when compared to the 
ER+ patient group. Platinum agents have recently emerged as the drug of interest. One 
clinical trial reported patients with stage II or stage III TNBC treated with cisplain in 
neoadjuvant setting resulted in a 22% pathological complete response rate (Silver, 
Richardson et al. 2010).  
Claudin low 
Recently, distinct tumors were found with characteristics of low gene expression of tight 
junction protein claudin 3, claudin 4, claudin 7 and E-cadherin (Herschkowitz, Simin et al. 
2007). Though claudin low tumors exhibit triple negative features (ER-/PR-/HER2-), in 
contrast to basal like tumors, claudin low tumors exhibit epithelial-to-mesenchymal 
transition features and stem cell associated phenotypes (Prat, Parker et al. 2010). Studies 
have demonstrated that expression profile of cancer stem cells (CD44+/24-) share similar 
profiles of claudin low samples from human breast tumors (Creighton, Li et al. 2009; 
Hennessy, Gonzalez-Angulo et al. 2009). Furthermore, this expression profile was found 
to be increased in post-treatment samples after neoadjuvant chemotherapy or hormonal 
therapy (Creighton, Li et al. 2009).  
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Chemoresistance 
Chemoresistance remains one of the main obstacles in cancer therapy. Though gene 
expression profiles regarding prognosis has been developed there is limited information 
on predicting drug resistance. Early chemo-sensitivity was predicted based on clinical 
parameters such as lymph nodes status, histological grades and size of the tumors 
(Lonning 2010).  
Chemoresistance is determined by different perspectives in experimental research and in 
clinical research. In the clinical aspect, factors of chemoresistance are evaluated by the 
patient’s overall survival, tumor size and cell contents (considered as pathological 
response) after chemotherapy (Lonning 2010). Experimental research accesses the 
therapeutic potential by killing cells in vitro, examining the inhibitory effects in terms of 
proliferation, gene expression and the inhibitory concentration at 50% (IC50). Over the 
past decade, molecular biology has provided insights on chemo-sensitivity, thus revealing 
mechanisms of chemoresistance and its relation to anti-apoptosis, transporters and cancer 
stem cells. In this review, three major factors that play an important role in 
chemoresistance will be discussed.  
Anti-apoptosis mechanisms 
The molecular events of apoptosis can be described in three steps, 1) apoptosis agents 
induction, 2) activation of caspases by signal transduction and 3) proteolysis of cellular 
components (Story and Kodym 1998). Whether the cell enters apoptosis is determined by 
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the balance of pro- and anti-apoptotic signals. Apoptosis can be activated via the intrinsic 
or the extrinsic pathways (Simstein, Burow et al. 2003). The extrinsic pathway requires 
ligands such as Fas ligand (FasL), tumor necrosis factor (TNF) binds onto the death 
receptor, activating the pro-apoptotic signal including caspase 8 and 6, leading to 
apoptosis (Poulaki, Mitsiades et al. 2001). Studies have suggested that chemotherapeutic 
agents induce apoptosis in cancer cells by inducing the expression of death receptor 
ligands such as Fas ligand (FasL) (Longley, Boyer et al. 2002). Binding of FasL to Fas 
either in a paracrine or autocrine manner activates caspase 8, thus activates the death 
receptor pathway (Ruiz-Ruiz, Munoz-Pinedo et al. 2000). Other ligands such as TNF- 
or its family members bind to its receptor TNFR1, leading to the recruitment of the 
intracellular death-inducing singaling complex, which serves as a docking site for 
procaspase-8 protein (Wallach, Varfolomeev et al. 1999). The intrinsic pathway involves 
the Bcl-2 protein family and the release of cytochrome c from the mitochondria (Herr and 
Debatin 2001). Bcl-2 and Bcl-xL reduce cytochrome c release (Simstein, Burow et al. 
2003). Proapoptotic protein Bid promotes the release of cytochrome c, activation of 
caspase adaptor Apaf1, thus activates caspase 9 (Poulaki, Mitsiades et al. 2001).  At this 
point, the extrinsic and intrinsic pathways are merged, resulting cleavage of DNA repair 
enzymes, intracellular molecules including cytoskeleton and nuclear proteins, thus 
entering the early apoptotic phase. It is important to note that the cytochrome 
c/Apaf1/caspase 9 pathway is most often activated by chemotherapeutics (Simstein, 
Burow et al. 2003). 
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The Bcl-2 and Bcl-xL proteins play an important role in anti-apoptosis. Bcl-2 resides in 
the cytoplasm until signals of apoptosis triggers its integration into the mitochondrial 
membrane (Story and Kodym 1998). Dimerization of Bcl-2 reduces the release of 
cytochrome c (Herr and Debatin 2001). Another anti-apoptotic protein Bcl-xL binds and 
inactivates caspase adaptor Apaf1, thus inactivates caspase 9 activities and the intrinsic 
death signaling pathway (Gross, McDonnell et al. 1999). Modulations of Bcl-2 families 
are observed in cells treated by chemotherapeutic agents. Doxorubicin decreases 
expression of Bcl-2 and increases Bax (pro-apoptotic, triggers the release of cytochrome 
c) expression (Leung and Wang 1999). Etoposide and 4-hydroperoxycyclophosphamide 
both increase Bax expression, furthermore, when used in combination, reduction of Bcl-2 
and increased levels of Bax are observed (Gibson, Fortney et al. 1999). Bcl-2 expression 
has always been correlated with chemoresistance and poor response in different cell types, 
including breast cancer cells MCF-7 (Piche, Grim et al. 1998). Introduction of Bcl-2 
antibody genes restore chemosensitivity in MCF-7 cells (Piche, Grim et al. 1998). 
Furthermore, clinically, unregulated Bax expression is correlated with good chemo 
response whereas increased level of Bcl-2 and Bcl-xL are correlated with poor response 
(Campos, Rouault et al. 1993; Sakakura, Sweeney et al. 1996; Zhang, Yu et al. 2000).  
The Akt pathway plays an important role in cell survival and chemoresistance. 
Dysregulation of the Akt signaling pathway promotes cell proliferation. Studies have 
shown that apoptosis is suppressed by Akt in dose-dependent manner and stimulate NF-
kB activation (Simstein, Burow et al. 2003). By using polyphosphate inhibitors that target 
phosphorylation of Akt, sensitivity of apoptosis is restored (Nicholson and Anderson 
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2002).  Downstream targets of Akt include Bad and NF-kB. Phosphorylation of Akt 
inactivates the proapoptotic protein BAD (Gross, McDonnell et al. 1999). Though Akt 
activates the NF-kB pathway, the NF-kB pathway is unique upon stimuli activation 
(including chemotherapeutic agents and Akt), i.e. it translocates into the nucleus and 
activates gene transcription including pro- or anti-apoptotic genes (Bours, Bentires-Alj et 
al. 2000). TNF- -kB 
activities (Lin, Devin et al. 1999). In contrast, NF-kB activates TRAF1/2 which 
suppresses caspase-8 activation, and activation of NF-kB pathway also suppresses Bax 
(pro-apoptotic) expression (Bentires-Alj, Dejardin et al. 2001).  
Long term exposure of chemotherapeutic agents increases susceptibility of cancer cells to 
chemoresistance. Potential targets of reversing chemoresistance include targeting 
activation of the death receptor pathway (intrinsic and extrinsic), Bcl-2 and Akt/ NF-kB 
pathway. Manipulation of these pathways may lead to increased potency and efficacy of 
chemotherapeutic response.  
Multidrug (MDR) transporters  
Overexpression of multidrug (MDR) transporters is characterized by ATP-binding 
cassette, thus the ABC superfamily remains to be one of the major reasons in 
chemoresistance. The ABC superfamily is divided into four subfamilies, ABCA, ABCB, 
ABCC and ABCG (Bush and Li 2002). Transporters associated in chemoresistance 
includes ABCA1, ABCA2, ABCA3 (ABCA family), ABCB1, ABCB4, ABCB5, 
18 
 
ABCB11 (ABCB family), ABCC1, ABCC2, ABCC3, ABCC4, ABCC5, ABCC6, 
ABCC10, ABCC11 (ABCC family) and ABCG2 (ABCG family)(Bush and Li 2002). 
The MDR transporters efflux a variety of substrates including dyes, antibiotics and 
chemotherapeutics including taxanes, anthracyclines, cisplatin, alkaloids, etc. Expression 
of MDR transporters is regulated by basal transcription, DNA response elements and 
genetic motifs (Bush and Li 2002).  
p53 tumor suppressor has been extensively studied in human cancers. p53 signaling is 
correlated with stress signals including DNA damage, arrest of DNA synthesis during 
chemo and radiation assault, inducing cell cycle arrest; this activates either DNA repair or 
apoptotic mechanisms (May and May 1999). Microarray data has revealed that p53 plays 
a role in apoptosis by upregulating Apaf-1 (adaptor protein for caspase 9) and Fas (death 
receptor) (Zhao, Gish et al. 2000; Kannan, Kaminski et al. 2001). Mutation of p53 and 
MDR transporters gene are involved in chemoresistance. Activation of ABCB1, the 
major MDR transporters in chemoresistance, is promoted by p53 mutant (Nguyen, Liu et 
al. 1994). Furthermore, wild type p53 downregulates ABCB1 expression through specific 
sequence binding on the ABCB1 promoter region (Strauss, Shivakumar et al. 1995).  
In breast cancer, expression of ABCB1 is correlated with p53. Nuclear accumulation of 
p53 and co-expression of ABCB1 is more prevalent in locally advanced breast tumors, 
which also provides poor prognosis and shorter survival (Linn, Honkoop et al. 1996). 
Another report has shown that p53 expression is strongly correlated with ABCB1 
expression in tumor samples compared pre- and post-chemo treated breast cancer tumor 
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samples in patients, though the correlation is independent of poor prognosis (Linn, 
Pinedo et al. 1997).  In colorectal cancer, accumulation of p53 and ABCC1 was found in 
adenomas and colorectal cancer, and also associated with tumor progression (Galimberti, 
Marchetti et al. 1998).  Expression of ABCC1 is associated with high tumor grade and 
late stage in prostate cancer (Van Brussel, Jan Van Steenbrugge et al. 2001).  Expression 
of mutated p53 and ABCC1 was also accessed in non-small cell lung cancer samples, 
showing significant correction and poorer prognosis (Oshika, Nakamura et al. 1998). 
Interestingly, not all tumor types exhibit the correlation between p53 mutant and ABCC1 
expression including testicular (Eid, Mingfang et al. 2000), gastric (Endo, Maehara et al. 
1996) and ovarian cancers (Coley 1997).  
Cancer stem cell exhibits high chemoresistance capability 
Cancer stem cells are a very rare population of cells (<1%) that are capable of self-
renewal and differentiation ability to their progenitor cells (Ginestier, Hur et al. 2007). 
High level of MDR transporters are found in normal and cancer stem cells thus providing 
a protection mechanism for exogenous assaults such as chemotherapeutics (Dean, Fojo et 
al. 2005). Mouse studies have suggested that mice deficient in MDR transporters are 
more susceptible to mutagens (Dean, Fojo et al. 2005). High expression of MDR in 
cancer stem cells have important therapeutic implications, as this rare population of cells 
exhibit chemoresistance and survive under exposure of chemotherapeutic agents and 
reconstitute the tumor.  
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Knockout mice studies suggested that MDR transporters do not play an important role in 
stem cell maintenance. Mice deficient in Abcg2, Abcb1 or Abcc1, and mice deficient in 
Abcb1 and Abcb2 all develop normally (Schinkel, Smit et al. 1994; Jonker, Buitelaar et al. 
2002; Uchida, Leung et al. 2002; Zhou, Morris et al. 2002; Zhou, Zong et al. 2003). 
However, these studies did not investigate the self-renewal capacity of stem cells by 
serial transplantation onto a secondary recipient. In contrast, overexpression of MDR 
transporters has been linked to cell differentiation. Mouse bone marrow cells transduced 
with ABCB1 exhibit significant stem cell expansion ex vivo (Bunting, Galipeau et al. 
1998). Overexpression of ABCG2 in bone marrow cells decreased mature progeny in 
both in vitro and in vivo (Zhou, Schuetz et al. 2001). Taken together, it is possible that the 
MDR transporters are not required for stem cell maintenance under normal circumstances, 
but might flavorly expressed in cancer. It is unclear that the expression of the MDR 
transporters on stem cells is the consequence of stem cell gene transcriptions or a 
causative factor. Poor clinical outcome is often associated with low degree of 
differentiation and correlated with transcriptomes resembling in embryonic stem cells 
(Ben-Porath, Thomson et al. 2008; Wong, Liu et al. 2008). Interestingly, such 
transcriptome can be induced by the dysregulation of MYC (Wong, Liu et al. 2008). It 
remains unclear that the high expression of the MDR transporters in tumors is 
functionally important for tumor progression aside from its drug efflux ability, or just a 
consequence of altered transcriptome in cancer cells, particularly in the case of MYC 
dysregulation.  
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Current clinical approach requires alternative method to overcome chemoresistance 
It is important to note that the functional redundancy in the MDR transporter families and 
its frequent over expression in tumors, makes the MDR transporters putative therapeutic 
targets. Specific MDR transporters, most notably ABCB1, ABCC1 and ABCG2 are often 
overexpressed in various cancers and efflux chemotherapeutic agents (Szakacs, Paterson 
et al. 2006; Teodori, Dei et al. 2006). Unfortunately, results of clinical trials have been 
disappointing in the past several decades. The first generation of ABCB1 inhibitors such 
as verapamil and cyclosporine A exhibit high toxicity in clinical application. Second 
generation ABCB1 inhibitors such as valspodar had increased its potency against ABCB1 
and decreased toxicity, however, did not show synergistic effect when combined with 
chemotherapy (Lhomme, Joly et al. 2008). A recent phase III study showed that patients 
with ovarian or peritoneal cancer treated with paclitaxel and carboplatin, failed to show 
benefits from the addition of valspodar (Lhomme, Joly et al. 2008). Currently third 
generation ABCB1 inhibitors such as zosuquidar are under development, and yet a phase 
II study of women with metastatic or locally recurrent breast cancer failed to find benefits 
in survival (Ruff, Vorobiof et al. 2009).  
Though modulation of the MDR transporters is disappointing in clinical trials which may 
indicate targeting MDR transporters in clinical settings may not be as important as 
experimental research suggested.  Complications of MDR inhibitors may have masked 
the success of MDR transporters inhibition in cancer treatment. Inhibition of the MDR 
transporters may decrease system clearance which may lead to increased toxicity and side 
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effects (Relling 1996). Such effects should be taken into consideration when developing 
MDR transporters inhibitors or when combined with chemotherapy in cancer treatment.  
Cancer stem cells 
There is increasing evidence indicating that a small number of stem cells in tumors that 
are capable of self-renewal as well as differentiation into multiple lineages. Cancer stem 
cells (CSCs) are defined by their tumor initiation ability in immunocompromised mice 
upon serial passages (self-renewal) and differentiate into non-self-renewing cells forming 
a tumor mass. The origin of CSCs remains to be controversial. It has been proposed that 
CSC may originate from three sources: 1) normal stem cells may transform into CSC 
with oncogenic events (Hope, Jin et al. 2004); 2) progenitor cells which are not fully 
differentiated may suffer from oncogenic transformation and acquire stem cell characters 
(Kucia and Ratajczak 2006; Li, Tiede et al. 2007); 3) Recent studies have demonstrated 
that differentiated cells may acquire CSC characteristics by inducing epithelial-
mesenchymal transitions (EMT) and transform into CSCs with self-renewal capacity and 
subsequent clonal expansion at the tumor site (Fig 1.1) (Mani, Guo et al. 2008; May, 
Sphyris et al. 2011).   
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Fig 1.1. Schematic representation of the origins of cancer stem cell. Cancer stem cell may 
araise from 1) normal stem cell, 2) progenitors with oncogenic events or 3) De-
differentiation of cells and acquired stem cell characteristics (Goldthwaite Jr 2011).  
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The conventional strategies in cancer treatment include surgery, radiation therapy, 
chemotherapy, targeted therapy such as using angiogenic inhibitors, blocking specific 
molecules involved in carcinogenesis, and yet, patients experience poor responses to the 
therapeutics or recurrence of cancer after surgery with metastasis and poor prognosis.  
The discovery of cancer stem cells (CSC) provides an alternative perspective in treating 
cancer. Cancer stem cells are a very rare population of cells found inside the tumor (Al-
Hajj, Wicha et al. 2003). Though very rare, CSC has the ability to reconstitute a tumor by 
its self-renewal and differentiation ability (Liu, Dontu et al. 2006; Ginestier, Hur et al. 
2007). Furthermore, upon chemo- and radiation therapy, CSC exhibits resistance 
mechanisms by upregulating genes which play important roles in cell cycle check points 
(Chappell and Dalton 2010), DNA repair (Bao, Wu et al. 2006), anti-apoptosis (Bertrand, 
Begaud-Grimaud et al. 2009; Chappell and Dalton 2010) and efflux (Moitra, Lou et al. 
2011). Upon encountering chemo- and radiation insult, CSCs would upregulate DNA 
repair genes and prevent itself from entering G2/M phase by activating cell cycle check 
point genes Chk1 and Chk2 (Bao, Wu et al. 2006). The adenosine triphosphate-binding 
cassette (ABC) transporters, efflux pumps that transport chemotherapeutics agents out of 
CSC (Moitra, Lou et al. 2011). These escape mechanisms make CSC difficult to 
eliminate. Indeed patients with high expression of CSC markers often experience poor 
treatment response and prognosis.  
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Identification of cancer stem cells 
Although the architecture of tumors has long been regarded as a heterogeneous structure, 
the existence of cancer stem cells has only been recently recognized. The first report 
demonstrated the existence of CSC was in 1997. Bonnet and Dick reported the existence 
of a cellular hierarchy in human acute myeloid leukemia (AML) by using stem cell 
markers CD34+/CD38- isolating cells that were able to transfer leukemia to 
immunosuppressed mice (Bonnet and Dick 1997). Subsequent studies have suggested 
that the CD34+ AMLs may arise from progenitor cells rather than from hematopoietic 
stem cells, i.e. leukemia maybe driven by multiple clones of leukemia stem cells (Qian, 
Fernald et al. 2002). Other than CSCs being identified in AML, CSCs have been 
subsequently identified in other solid tumors including breast, brain, colon, liver and 
pancreas (Al-Hajj, Wicha et al. 2003; Singh, Clarke et al. 2003; Collins, Berry et al. 2005; 
Li, Heidt et al. 2007; Ma, Chan et al. 2007). Studies have also provided evidence that 
CSCs mediate tumor metastasis, and exhibit resistance to radiation and chemotherapy, 
which are contributing factors to tumor recurrence (Wicha, Liu et al. 2006; Liu, Patel et 
al. 2010).  
Knowing that CSCs play an important role in carcinogenesis, from tumor initiation to 
metastasis, one must understand the properties of CSCs and assays in studying CSCs. In 
this review, we will discuss the identification of CSCs by two established markers in 
breast cancer, CD44+/CD24- and ALDH.   Differences of cell division patterns are found 
between normal mammary stem cells and breast cancer stem cells. Evaluation of CSCs 
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could be studied by performing the mammospheres/tumorspheres assay, which allows 
study of CSCs self-renewal and differentiation potential in vitro. Xenograft experiments 
allow evaluation of CSCs tumor initiation power and resemblance of parental tumors.  
BCSC identified by Cell Surface Marker: CD44+/CD24- 
The initial description of breast cancer stem cells (BCSCs) involves the isolation of this 
rare population in human breast tumors by surface marker expression CD44+/CD24-/lin- 
(Al-Hajj, Wicha et al. 2003). The CD44+/CD24-/lin- cells were able to initiate tumors in 
immunosuppressed nonobese diabetic/severe combined immunodeficient mice 
(NOD/SCID) with as few as 200 cells whereas 20,000 cells from the same tumor without 
surface markers sorting failed to initiate tumors (Al-Hajj, Wicha et al. 2003). It is 
important to note that tumors generated from BCSCs resemble the heterogeneity of the 
initial tumor.  
If each BCSC markers are evaluated independently, CD44 is commonly expressed in 
primary tumors, CD24 and ALDH are expressed in minority of cases. Within the two 
markers (CD44 and CD24), CD44 expression is the most comparable between tumors 
and cell lines (Pece, Tosoni et al. 2010). High CD44 expression is often found in basal-
like tumors with poor prognosis and aggressive basal-like cell lines like MDA-MB-231, 
MDA-MB-468, BT 549 and BT-20, and is associated like basal markers such as 
cytokeratin 14 and vimentin (Pece, Tosoni et al. 2010). Studies have also shown that 
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CD44+ cells display a mesenchymal stem cell like profile with high gene expressions 
involved in cell motility, proliferation and angiogenesis (Pece, Tosoni et al. 2010).  
CD44 expression has also been shown as a prognostic indication. Expression of CD44 is 
associated with distant metastasis, lymph node status and decreased patient survival 
(Kusumbe and Bapat 2009). This could be due to CD44 expression as correlated with 
basal-like tumors which are usually metastatic and the stem-like gene expression profile 
as correlated with shorter distant metastasis-free survival (Pece, Tosoni et al. 2010). 
These results strengthen the prognostic value of CD44 in clinical practices.  
Expression of CD24 is discrepant in primary tumors and cell lines. Only a small 
percentage of tumors are CD24+ but most cell lines including T47D, MCF7, BT474, 
MDA-MB-468 are CD24+ (Aleo and Pece 1977). Compared to cell surface marker CD44, 
CD24 expression localized on the cell surface and cytoplasm, which could explain why 
opposite results of CD24 expression are reported in different studies as evaluation of 
CD24 expression (either cytoplasmic or extracellular) is not consistent between studies 
(Honeth, Bendahl et al. 2008; Schubert, Herbert et al. 2011).  
In tumors, CD24+ cases are frequently found in luminal A breast cancer and rarely 
detected in basal-like breast cancer (Aleo and Pece 1977), suggesting CD24 expression is 
related to differentiated tumors whereas CD24- have stem-like characteristics. However, 
most breast cancer cell lines express high level of CD24 including luminal, HER2 and 
some basal like breast cancer with the exception of MDA-MB-231.  
28 
 
Similar trends are found when CD44 and CD24 are combined for evaluation in breast 
cancer cell lines and tumors. Basal-like tumors and basal-like cells MDA-MB-231 both 
express high percentage of CD44+/CD24- cells. Though basal-like cells MDA-MB-468 
express both CD44/CD24, MDA-MB-468 maintained higher levels of differentiation 
whereas MDA-MB-231 cells maintained poorly differentiated basal/mesenchymal 
phenotype. Previous studies have reported that CD24+ luminal progenitors may be an 
origin of basal-like carcinoma (Lim, Vaillant et al. 2009), which could explain why basal-
like breast cancer cells have CD24+ expression. Since it is common to see CD44+ but not 
CD24 expression in basal-like breast cancer with its aggressive characteristics, and 
previous studies have shown that CD44+/CD24+ cells can give rise to CD44+/CD24- 
cells (Meyer, Fleming et al. 2009), loss of CD24 expression in basal like tumors could be 
a consequence during tumor progression .  
In addition, it has been shown that distant breast cancer metastasis are enriched in CD24+ 
cells, which could be due to phenotypic change from CD24+ to CD24- by epithelial-to-
mesenchymal transitions in pre-metastastic stage (Mani, Guo et al. 2008), generating 
cells with CSC characteristics, and mesenchymal-to-epithelial transitions, a reversion 
from CD24- to CD24+ after distant metastasis has been established.  
BCSCs identified by Intracellular Marker: ALDH 
Aldehyde dehydrogenase (ALDH) has been demonstrated as a marker of BCSC and 
normal mammary stem cell (Ginestier, Hur et al. 2007), which suggests maybe that 
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ALDH+ cells are targets of transformation and cancer initiation from normal to pre-
malignant state which is in contrast to CD44+/CD24- cells that only identify BCSC.  
In breast cancer, studies have shown that ALDH+ cases in invasive breast cancer are 
<20%, ranging from 5%-19% (Morimoto, Kim et al. 2009; Kim, Kim et al. 2010). 
Predominant ALDH expression is often found in basal-like breast tumors. In terms of 
breast cancer cell lines, ALDH expressions are also higher in basal-like breast cancer cell 
lines, interestingly, high ALDH expressions are also found in HER2+ cell lines such as 
SkBr3 cells and BT474 (Aleo and Pece 1977). It is important to note that the 
CD44+/CD24- population may not overlap with ALDH+ cells, suggesting the different 
origins of CSC may give rise to distinct molecular profile of breast cancer.  Breast cancer 
cells MDA-MB-231 contain a large population of CD44+/CD24- cells but low 
percentage of ALDH+ cells, in contrast, HER2+ cells SkBr3 and BT474 contains high 
percentage of ALDH+ cells but not CD44+/CD24- (Morimoto, Kim et al. 2009), 
reinforcing the idea that different molecular subtypes of breast cancer may have different 
CSC origin.  
Other than identification of BCSCs, ALDH has also been shown to be correlated with 
high grade breast tumors and may be a promising marker for prognosis (Ginestier, Hur et 
al. 2007). Expression of ALDH correlates with clinical outcomes in breast cancer and 
ovarian cancer.  Strong ALDH expression correlates with poor prognosis in breast cancer 
but not in ovarian cancer. Strong expression of ALDH in ovarian cancer correlates with 
favorable prognosis (Chang, Liu et al. 2009). This discrepancy suggest that, depending on 
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the cancer site location, markers for identifying CSC in one organ may or may not be 
useful for identifying CSC in another organ. 
In conclusion, though CD44+/CD24- and ALDH+ are well established markers for CSC 
identification, the CD44+/CD24- cells are notably found in basal-like carcinomas, which 
could originate from mammary stem cells; in contrast, ALDH+ cells are found in HER2+ 
and basal-like carcinomas, suggesting these cells may originate from luminal progenitors. 
Further investigation is required for the relationship of different molecular subtypes 
corresponding to its CSC markers, allowing translation of identifying CSC by markers in 
clinical practice.  
The cell division pattern: hints in understanding the self-renewal in BCSCs 
Cicalese et al have shown that by using the lipophilic dye PKH26 before culturing 
tumorspheres, one can identify CSC by PKH26 dye diffusion (Cicalese, Bonizzi et al. 
2009). As differentiated progenitors are dividing actively, and symmetrically, the PKH 26 
dye will diffuse into the daughter cells during mitosis. In contrast, CSC retains PKH 26 
dye by its dormant quiescence state accompanied by asymmetrical division. After 7-10 
days of incubation, only 1-2 cells retain high density of PKH26 dye on their cell 
membranes (Cicalese, Bonizzi et al. 2009). Direct imaging of initial self-renewing 
division of mammary stem cells revealed that, upon cell division, two daughter cells with 
different proliferative potential are generated. One daughter cell stayed in its quiescent 
state and the other cell proliferates actively. The protein Numb, a cell fate determinant 
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protein that is evolutionarily conserved in both invertebrates and mammals, is 
intracellularly localized in the cell retaining PKH26 fluorescence dye, which showed that 
the cell division is also intrinsically asymmetric (Cicalese, Bonizzi et al. 2009).  
Similar to the wild type mammospheres, tumorspheres derived from HER2+ mouse 
mammary tumor cells are composed of a minor subpopulation of BCSC and are mainly 
composed of progenitors at different stages of differentiation. In contrast to breast stem 
cells in mammospheres that retained the PKH26 dye, BCSC was found in cells that did 
not retain PKH26 dye, indicating BCSC in HER2+ tumors may undergo multiple rounds 
of symmetrical cell division without losing the self-renewal ability, thus in a way 
expanding the BCSC population without losing the differentiation potential. Such 
observation could be explained by the alternate usage of symmetrical and asymmetrical 
division in BCSCs. Indeed, the frequency of symmetrical division progressively 
decreased in the process of mammospheres growth, suggests that the mammospheres 
culture condition may favor asymmetrical division (Cicalese, Bonizzi et al. 2009).  
Though the mammary gland stem cells are capable of self-renewal, the self-renewal 
ability is limited in culture and may only be serially transplanted up to 6-7 generations 
(Daniel, De Ome et al. 1968). In contrast, BCSCs derived from HER2+ mouse mammary 
tumors are considered to be almost immortal and may be serially transplanted more than 
7 generations. Furthermore, BCSCs derived from HER2+ mouse mammary tumors also 
exhibited asymmetrical division, which suggests that these cells may also be responsible 
for maintaining tumor heterogeneity and the expansion of the tumor mass.  
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The regulation of asymmetrical and symmetrical division may be influenced by p53 
status of BCSCs. Mouse studies revealed that mammary stem cells in p53 knocked out 
mice exhibited symmetrical division in vitro and in vivo. Indeed wild type mice with 
increased p53 activities decreased regenerative abilities of mammary gland 
transplantation in serial transplantation experiments (Gatza, Dumble et al. 2008). 
Restoration of p53 activities in HER2+ mammospheres drives BCSCs division pattern 
from sysmmetrical division to asymmetrical divisions (Cicalese, Bonizzi et al. 2009). The 
frequency of tumorspheres formation is reduced in HER2+ derived tumorspheres after 
restoration of p53 activities by switching from symmetrical to asymmetrical divisions. 
The physiological function of p53, on top of tumor suppressing function, could also be 
involved in stem cell maintenance by keeping stem cells in asymmetrical division and 
self-renewal state. The stem cell maintenance function of p53 is not specific only to 
breast tissues. Studies on neural stem cells have shown that loss of p53 induced increased 
self-renewal capabilities and expansion of neural stem cells (Meletis, Wirta et al. 2006), 
suggesting that the effect of p53 may represent a general function to different tissues.  
Mammospheres/Tumorspheres Assays: Measures of Self-renewal and Differentiation 
The mammospheres assay, adapted from the neurospheres assay, is an assay for culturing 
mammary stem cells. Formation of mammospheres is facilitated by serum free mediums 
supplemented with EGF or bFGF. Mammospheres are highly enriched with 
undifferentiated cells. Single cells isolated from mammospheres generate multilineage 
progenitors when cultured in differentiating condition, i.e., under serum condition.   
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Dontu et al have shown that freshly isolated mammary cells contained ~8% mammary 
cells with bi-lineage potential, which is enriched up to 68% when cultured in 
mammospheres condition forming primary mammospheres, and almost 98% in secondary 
mammospheres and mammospheres in later passages (Dontu, Abdallah et al. 2003). 
Though there were controversies that mammospheres may form due to cell aggregation, 
serial dilution experiments have shown that mammospheres are able to form at clonal 
level.  
Cells in mammospheres represent mammary stem cells that have self-renewal abilities 
and are able to give rise to multi-lineage progenitor cells which are capable of multi-
lineage differentiation. As the true stem cells are the only cells capable of self-renewal, 
all other cell types are subjected to differentiation, and terminally differentiated after a 
series of cell divisions. Furthermore, if the mammosphere initiation cells are early 
multipotent cells rather than the true stem cell, the number of mammospheres should 
decrease after each passage, as each round of passage cells in the mammospheres have 
been stimulated with one round of differentiation. The size of mammospheres should also 
decrease as cells are more differentiated. The mammospheres forming abilities also 
reflect the number of true stem cells. Frequency of spheres formation should remain 
constant if all primary spheres are formed by true stem cell. Decrease of spheres 
formation indicates that some of the primary spheres are formed by early multi-potent 
progenitors.  
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Immunostaining of mammospheres provide the hierarchy of cell types inside the 
mammospheres. Earlier progenitors express CD10, alpha6-integrin and cytokeratin 5 
whereas late progenitors (still multi-potent) express ESA and cytokeratin 14 (Stingl, 
Eaves et al. 1998; Gudjonsson, Villadsen et al. 2002). Ductal epithelial cell lineage 
(MUC1 and cytokeratin 18) and myoepithelial lineage (ASMA) are not expressed in cells 
isolated from mammospheres but are found in mammospheres derived cells after cultured 
in collagen substrate (Stingl, Eaves et al. 1998; Gudjonsson, Villadsen et al. 2002).  
Currently resources for culturing mammospheres/tumorspheres include using primary 
tissues/tumors (human or mouse), mouse xenografts and cancer cell lines. Cells are 
cultured in low-attachment conditions with serum free media in the presence of EGF and 
bFGF. After 7-14 days of incubation, the stem cells/CSCs form spheres colonies in 
suspension. Formation of the spheres represents the initial stem cell/early progenitor cells 
in the parental population. Spheres may also be subjected to enzymatic digestion for 
passages, or immunostained for differentiated cell lineages. Taken together, the 
mammospheres/tumorspheres are enriched population of mammary cells with bi-lineage 
potential, capable of self-renewal and differentiation into multi-lineages.  
Functional Assay in vivo: Xenografts experiments 
The properties of CSCs may also be examined in vivo. The tumorigenicity of CSCs can 
be evaluated by serial transplantation experiments. The number of cells implanted in the 
mammary fat pad may be an indication of tumor initiation abilities of CSCs. By using 
35 
 
FACS technology, one may isolate putative BCSCs and subsequently inoculate into 
immune-compromised mice to observe the tumor initiation power of isolated BCSCs 
compared to non-BCSCs. Al-Hajj et al, have demonstrated that isolated CD44+/CD24- 
cells initiated tumors with as low as 200 cells whereas CD44-/CD24+ cells do not initiate 
tumors even up to 20,000 cells (Al-Hajj, Wicha et al. 2003). Ginester et al, have isolated 
ALDH+ cells and are able to initiate tumors with 150 cells, and even lower number of 
cells to initiate tumors when isolating cells with combined markers CD44+/CD24-
/ALDH+ (Ginestier, Hur et al. 2007). Cells that retained high amounts of PKH26 dyes 
initiated tumors with only a few cells (Cicalese, Bonizzi et al. 2009). These studies 
indicated that BCSCs are highly tumorigenic and the xenografts model (inoculating low 
numbers of cells into immuno-compromised mice) is an animal model for BCSCs 
validation. Furthermore, tumors initiated by BCSCs resemble cell morphology, stages of 
differentiation and molecular subtypes of the original tumors (Boven, Winograd et al. 
1992), suggesting that the isolated BCSCs from parental tumors are responsible for 
initiating and constituting the tumor mass.  
Taken together, tumor xenografts in mice demonstrated the maintenance of heterogeneity 
of tumors including cell differentiation, morphology and molecular signatures of the 
original tumors. Furthermore, tumor xenografts are the direct way to examine the tumor 
initiation (inoculating low numbers of cells), self-renewal ability (serial transplantations) 
and differentiation capacities (reconstitution of the tumor mass) of CSCs.  
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It is important to note that validation of CSCs requires both in vitro and in vivo 
experimental research. Dontu has argued that cells with CD44+/CD24- phenotype may 
only be associated with CSCs in certain breast cancers such as basal-like breast cancer 
(Dontu 2008). Cancers that do not contain these BCSC phenotypes may be driven by 
CSCs expressing different biomarkers, thus making identification of BCSCs in clinical 
practice difficult. In order to progress in understanding BCSCs, the combination of in 
vitro and in vivo experimental approach must be adapted to improve our understanding 
on how BCSCs drive tumor growth and evolution.  
Prolactin (PRL) 
PRL is a 23-kDa peptide hormone that is closely related to growth hormone. PRL is 
secreted by the lactotrophs in the anterior pituitary and plays an important role in 
mammary gland development (Clevenger, Chang et al. 1995). Secretion of PRL is also 
found in other cell types including immune cells, brain cells and uterus cells.  PRL is also 
produced by the breast epithelium in an autocrine/paracrine fashion and functions as a 
cytokine (Clevenger, Chang et al. 1995; Ginsburg and Vonderhaar 1995; Ben-Jonathan, 
Liby et al. 2002; Clevenger, Furth et al. 2003).  
The physiological role of PRL in mammary glands has been described by the PRL (PRL
-
/-
) and PRLR (PRLR
-/-
) knockout (KO) mouse model. Although mammary gland 
development is normal prepubertally in both PRL
-/- 
and PRLR
-/-
 mice (Hennighausen and 
Robinson 2001; Hovey, Trott et al. 2002), for mature wild type mice, PRL is essential for 
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ductal branching and terminal end buds formation (Hinck and Silberstein 2005) while the 
PRL
-/- 
and PRLR
-/-
 KO mice failed to develop normal mammary structure (Fig 1.2 and 
Fig 1.3) (Ormandy, Binart et al. 1997; Brisken, Kaur et al. 1999; Vomachka, Pratt et al. 
2000). The terminal end buds structure is restored in PRL
-/- 
mice by engrafting pituitaries 
from PRL heterozygote (PRL
+/-
) mice (Vomachka, Pratt et al. 2000). These studies 
indicate that PRL plays an important role in mammary development after entering 
puberty.  
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Fig 1.2. Prolactin knockout mice failed to develop ductal structure and terminal end buds 
in mammary gland of 5 months old virgin mice (Horseman, Zhao et al. 1997). Arrows are 
indicating the location of the ductal structure terminal end buds.  KO, knockout.   
PRL   Wild type PRL   KO 
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Fig 1.3. Prolactin receptor knockout mice failed to develop terminal end buds during 
mammary gland development in 14 weeks old virgin mice (Ormandy, Naylor et al. 2003). 
Arrows are indicating the location of the terminal end buds.  KO, knockout.   
PRLR Wild type 
PRLR   KO 
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Prolactin receptor and its multiple isoforms 
The action of PRL is mediated through the PRL receptor (PRLR) which belongs to the 
class I cytokine receptor superfamily. The receptor binds PRL with high affinity. The 
PRLR is composed of three separate regions: an extracellular region with five cysteines 
as the binding site of PRL, a single transmembrane region and an intracellular domain 
required for signal transduction that lacks intrinsic kinase activity (Fig 1.4). The 
disulfide-linked cysteines in D1 subdomain are involved in ligand binding, while the 
WSXWS motif in D2 subdomain is required for correct folding and cellular trafficking. 
Box 1 in the intracellular domain is highly conserved in the cytokine receptor family and 
serves as the docking site for Jak2. Function of Box 2 is unclear (Chon-HwaTsai-Morris 
2011).  
Multiple isoforms of PRLR have been identified resulting from alternative splicing (Fig 
1.4). The three isoforms are referred to as long, intermediate or short forms of PRLR. The 
long form is the full length functional receptor. Both the long and intermediate form 
share the same structure for ligand binding, but the intermediate form is truncated in its 
C-terminus, though capable of Jak2 activation, stimulation of the intermediate form 
requires high concentration binding with minor proliferation effect (Chon-HwaTsai-
Morris 2011). The short form shares the similar intracellular structure of the long form 
but lacks the ligand domain structure, making the short form effective in signal 
transduction but it exhibits reduced affinity of the ligand (Chon-HwaTsai-Morris 2011). 
The function of different isoforms remains unclear, as different expressions of various 
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isoforms are observed in mammary tissues and cell lines (Clevenger, Furth et al. 2003). 
Future investigation is suggested for the functions of different PRLR isoforms.  
 
Fig 1.4. Schematic representation of multiple isoforms of PRL receptor. Different 
isoforms are referred to as long, intermediate (IF) or short (S1) form. EC, extracellular 
domain; TM, transmembrane domain; IC, intracellular domain; D1, D2: N-terminal 
subdomain; WS: WSXWS motif; C, cysteine; aa, amino acid 
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Mechanism of PRL signaling 
Cell response of PRL is by the binding of PRL to its receptor, PRLR. Receptor 
dimerization for PRL is required for the activation of its receptor, thus leading to cell 
proliferation (Ihle 1996). It is important to note that high concentrations of PRL may 
result in an antagonistic effect and blocking of signal transduction as the receptors and 
PRL failed to form heterodimer complex (Fuh, Colosi et al. 1993).  
Upon PRLR dimerization, Jak2 is activated thus phosphorylates other substrates and links 
to multiple downstream pathways such as STATs, Ras-MAPKs and PI3K (Fig 1.5) (Rane 
and Reddy 2000). Activation of the Jak/STAT pathway by PRL has been observed in 
multiple breast cancer cell lines, including T47D, MCF-7 and BT-20 where PRL 
treatment resulted in increased phosphorylation of STAT 1, 3 and 5 (DaSilva, Rui et al. 
1996; Schaber, Fang et al. 1998; Llovera, Pichard et al. 2000). The STAT proteins are 
important transcriptional regulators where they serve as signal transducers in the 
cytoplasm and transcription activator in the nucleus (Cataldo, Chen et al. 2000). Both 
STAT3 and 5 are involved in PRL activation of the cyclin D1 promoter but STAT1 is 
growth inhibitory (Brockman, Schroeder et al. 2002).  
Other than the Jak/STAT pathway, PRL has also been shown to activate the MAPK 
pathway (Clevenger, Torigoe et al. 1994; Das and Vonderhaar 1996). In T47D cells, 
activation of MAPK pathway by PRL is associated with the increase of Grb2 and Sos, 
and depending on the phenotype of the tumor cells, PRL/PRLR pathway may cross-talk 
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with other factors such as erbB2, thus increasing association with Grb2 and activing the 
Ras-MAPK pathway (Das and Vonderhaar 1996; Yamauchi, Yamauchi et al. 2000). The 
MAPK pathway is one of the important cellular pathways that controls the growth and 
survival of many human tumors (Sebolt-Leopold and Herrera 2004).  
Prolactin also stimulates the PI3K pathway. Dominquez-Caceres et al have demonstrated 
that PRL induced c-Myc expression and increased cell survival exists through the 
activation of Src/Akt pathway in lymphoid cells (Dominguez-Caceres, Garcia-Martinez 
et al. 2004). Recent reports have demonstrated the direct link of PI3K/Akt pathway in 
mammary gland differentiation and lactation. Activation of the PI3K/Akt pathway 
induces autocrine secretion of PRL in the mammary gland, thus leading to STAT5 
activation and terminal mammary epithelial differentiation (Chen, Stairs et al. 2012).  
  
44 
 
 
 
 
Fig 1.5. Schematic representation of the PRL/PRLR signaling pathways. The major 
signal transduction pathway of Jak/STAT, MAPK, Akt and Rac pathways resulting in 
cell differentiation, proliferation, survival and motility.  
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Overview and rationale of current work 
Despite the clinical efficacy of chemotherapeutic therapy, conventional treatments have 
not been shown to target BCSCs effectively (Tan, Piwnica-Worms et al. 2000; Wang, 
Guo et al. 2007; Raguz and Yague 2008). Differentiation therapy has been proposed as an 
alternative treatment approach in treating cancer (Leszczyniecka, Roberts et al. 2001; 
Azzi, Bruno et al. 2011). As differentiated cells are more susceptible to chemotherapy 
(Azzi, Bruno et al. 2011), differentiation of BCSCs may increase susceptibility to 
chemotherapeutic agents. Here we propose to use prolactin (PRL), a pituitary hormone 
responsible for mammary gland development and lactation (Hennighausen and Robinson 
2001; Hovey, Trott et al. 2002; Hinck and Silberstein 2005), combining with 
chemotherapeutics to improve the therapeutic outcome. Previously Pece et al., have 
demonstrated the similarities of transcriptional content between human normal mammary 
gland stem cells and cancer stem cells, in which poorly differentiated cancers displayed 
higher content of BCSCs than well-differentiated tumors (Pece, Tosoni et al. 2010). Here 
we hypothesize that since PRL plays a critical role in mammary gland development, in 
which it promotes proliferation and differentiation of mammary stem cells, PRL may also 
induce differentiation of BCSCs, thus making them susceptible to those agents targeting 
differentiated cells. In this study, we have explored the application of PRL as a 
differentiation agent in increasing effectiveness of chemotherapeutic treatments. 
Treatment of PRL showed a decrease of tumorspheres formation in a concentration 
dependent manner and modulate cell division pattern in BCSCs. Combination of PRL 
and cisplatin further reduced tumorspheres formation. Both mouse xenograft model and 
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neu mouse model have demonstrated that PRL and cisplatin combination effectively 
inhibit tumor growth in vitro and in vivo.  
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CHAPTER TWO 
MATERIALS AND METHODS 
 
Cell Culture 
Human breast cancer cell lines T47D, MCF7, HCC1954, SKBR3 and murine breast 
cancer cell line 4T1 were purchased from American Type Culture Collection (ATCC, 
Manassas, VA). The cells were propagated in RPMI supplemented with 10% FBS and 1 
g/mL of Gentamicin (Invitrogen, Carlsbad, CA). Mammary carcinoma from neu 
transgenic mouse A (MCneuA) cells were generously provided by Dr. Michael Campbell 
from the University of California, San Francisco. MCneu A cells were propagated in 
DMEM supplemented with 10% FBS and 1 g/mL of Gentamicin. Primary mammary 
tumor cells isolated from neu transgenic mice were cultured in DMEM/F12 
supplemented with 10% FBS and 1 g/mL of Gentamicin (Invitrogen).  
Proliferation Assay 
Breast cancer cells SKBR3 and MCneuA cells were harvested at 80% confluency and 
seeded at a concentration of 5x10
3
cells/100L/well into 96-well plates in RPMI or 
DMEM corresponding to the cell culture medium and supplemented with 10% FBS and 1 
g/mL of Gentamicin. Cells were incubated at 37oC overnight for attachment. The 
48 
 
medium was removed the next day and washed by PBS three times prior to addition of 
doxorubicin (4ng/mL – 1g/mL), cisplatin (0.125g/mL – 40g/mL), or combination of 
PRL (100ng/mL) with the corresponding chemotherapeutics in RPMI or DMEM 
supplemented with 5% FBS. Cells were treated for an additional 72 hours. After 
treatment, the culture medium was removed and washed with PBS three times prior to 
adding 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl-2H-
tetrazolium/phenazine methosulfate (MTS/PMS) which was diluted at a 1:6 ratio (Cell 
Titer 96 Aqueous non-radioactive cell proliferation kit; Promega, Madison, WI). The 
relative viability of the cells were determined by colorimetric measurement of the 
reduction of MTS by the living cells using the TECAN GENios PRO plate reader. Plates 
were read at 492nm and all experiments were carried out in quadruplicate and repeated 
three times. Cell viability was calculated as a percentage of control treatments.  
FACS analysis 
Both T47D and MCneuA cells were harvested at 80% confluency and washed by PBS 
three times prior to seeding into 1x10
5
 cells/2mL/well in 6-well plates and in RPMI or 
DMEM supplemented with 10% FBS and 1 g/mL of Gentamicin. Primary mammary 
tumor cells were isolated from tumors originated from neu transgenic mice. Tumors were 
minced into paste and enzymatically dissociated in 10mL of 0.4% trypsin for 10 minutes 
at 37
o
C. After the 10 minutes incubation, 30mL of PBS was added and the tube was 
inverted several times. Cell suspensions were then filtered through 40m strainer and re-
suspended in 1mL of PBS prior to seeding into 6-well plates.  
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All cells were incubated at 37
o
C overnight for attachment in RPMI or DMEM 
supplemented with 10% FBS. The medium was removed the next day and washed by 
PBS three times prior to the addition of PRL (100ng/mL), doxorubicin (50ng/mL), 
Paclitaxel (7ng/mL), cisplatin (2g/mL) or in combination of PRL and its corresponding 
chemotherapeutics in RPMI or DMEM supplemented with 5% FBS. Cells were treated 
for 72 hours prior to a staining of fluorescence markers (ALDH and Sca-1) and subjected 
to FACS analysis. Please note that for the PKH26 fluorescence marker staining, cells 
were pre-stained prior to seeding.  
After treatment, cells were washed with PBS three times for the preparation of FACS 
analysis.  
ALDEFLUOR Assay (ALDH) 
The ALDEFLUOR assay was followed according to the manufacturer’s protocol 
(StemCell Technologies, Durham, NC). Cells were prepared at the concentration of 1x10
6 
cells/mL and resuspended in 1mL of ALDEFLUOR Assay buffer. Two 2mL 
microcentrifuge tubes were prepared. One microcentrifuge tube was added with 5L of 
diethylaminobenzaldehyde (DEAB). Another microcentrifuge tube with 2mL of cells was 
added with 5L of activated ALDEFLUOR reagent. Once the activated ALDEFLUOR 
reagent was mixed in cells solution, 500L of cells with the activated ALDEFLUOR 
reagent was transferred into the microcentrifuge tube with DEAB. Both microcentrifuge 
tubes were incubated at 37
o
C for 45 minutes and subsequently washed twice in ice-cold 
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ALDEFLUOR assay buffer. Cells were resuspended- in 500L of ALDEFLUOR assay 
buffer prior to FACS analysis. Schematic representation of the preparation for the 
ALDEFLUOR assay is shown in Fig 2.1.  
PKH26 fluorescence marker 
Primary mammary tumor cells were washed with 5mL PBS three times prior to staining. 
1.25x10
6
 Cells were re-suspended in 125L of diluent C (Sigma). Simultaneously, 1L 
of PKH26 linker (PKH26GL-1KT; Sigma) was pre-mixed in 125L of diluent C and the 
diluted PKH26 fluorescence marker was added into the re-suspended cells. Cells were 
incubated at room temperature for 10 minutes and subsequently washed three times in 
1mL PBS prior to incubation treatments in RPMI or DMEM supplemented with 5% FBS 
and 1 g/mL of Gentamicin. After treatment, cells were harvested by trypsinization and 
washed three times with PBS. Cells were resuspended with 500L of PBS at the 
concentration of 5x10
5
 cells/mL prior to FACS analysis.  
Sca-1 extracellular surface marker 
Primary mammary tumor cells were washed with 5mL PBS prior to seeding and 
treatments. After treatment, cells were washed with PBS three times prior to staining. 
Cells were resuspended at 1x10
7 
cells/mL in 30L of ice-cold PBS. Subsequently, 0.2g 
of Sca-1 antibody conjugated with phycoerythrin (PE) (Cat#553336; BD Pharmingen; 
Franklin Lakes, NJ) was added and incubated on ice for 30 minutes in dark. Cells were 
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washed three times with ice-cold PBS and resuspended in 600L of PBS prior to FACS 
analysis.  
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Fig 2.1. Schematic representation of the ALDEFLUOR Assay. Cell samples were mixed 
with ALDEFLUOR reagent and green fluorescence is released upon cleavage of 
ALDEFLUOR reagent by ALDH enzymes in cells. Addition of DEAB allows inhibition 
of ALDH enzymes, thus providing a control for background noises.   
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Tumorspheres 
The tumorsphere medium was composed of DMEM/F12 (Sigma, St. Louis, MO) 
supplemented with 0.4% BSA, 5g/mL insulin (Sigma), 20ng/mL basic fibroblast growth 
factor (Sigma) and 20ng/mL epidermal growth factor (Sigma) unless otherwise specified. 
Breast cancer cells MCF-7 and HCC1954 were harvested at 80% confluency and seeded 
in ultra-low attachment flask (Corning, Tewksbury, MA) at 2500 cells/mL in primary 
tumorspheres formation. Cells were cultured in tumorspheres medium for 7 day before 
enzymatic dissociation for secondary tumorspheres formation in 24-well ultra-low 
attachment plates at 1000 cells per mL (Corning). Formation of secondary tumorspheres 
was evaluated after 7 days of treatment. For the effect of PRL in tumorspheres, cells were 
treated with PRL (500 ng/mL) for 7 days and tumorspheres were subsequently 
dissociated into single cells for secondary tumorsphere formation. These secondary 
tumorspheres received no treatment. Formation of secondary tumorspheres indicates the 
effects of PRL in primary tumorspheres in BCSCs (Fig 2.2). In contrast, experiments on 
PRL enhancing cytotoxic effect of cisplatin, PRL and cisplatin treatment were added in 
secondary tumorspheres culture and there was no treatment in primary spheres culture 
(Fig 2.3).  
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Fig 2.2. Schematic representation of tumorspheres assay receiving PRL treatment. Cells 
were subjected to tumorspheres culture and PRL treatment was added in primary spheres 
formation. Cells isolated from primary spheres were seeded for secondary tumorspheres 
formation with no treatment. Tumorspheres were counted after 7 days of incubation.  
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Fig 2.3. Schematic representation of tumorspheres assay receiving PRL treatment. Cells 
were subjected to tumorspheres culture and there was no treatment in primary 
tumorspheres formation. Cells isolated from primary spheres were seeded for secondary 
tumorspheres formation with PRL and cisplatin combination treatment. Tumorspheres 
were counted after 7 days of incubation. 
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PKH26 assay 
Breast cancer cells MCF-7 and HCC1954 were harvested at 80% confluency. Cells were 
washed with 5mL PBS three times prior to staining. 1.25x10
6
 Cells were re-suspended in 
125L of diluent C (Sigma). Simultaneously, 1L of PKH26 linker (Sigma) was pre-
mixed in 125L of diluent C and the diluted PKH26 linker was added into the re-
suspended cells. Cells were incubated at room temperature for 10 minutes and 
subsequently washed three times in 1mL PBS prior to incubation in tumorspheres culture. 
Tumorspheres with 4-8 cells after 4 days of incubation were harvested by centrifuging at 
700g for 15 minutes. Spheres were subsequently re-suspended in 1mL of Hoechst 33342 
nuclei stain at 10g/mL for 30 minutes at room temperature. Nuclei stained spheres were 
washed by 1mL PBS one time and mounted on a microscope slide in 50% glycerol mixed 
with PBS. Spheres were examined microscopically by Nikon Eclipse confocal 
microscope (Nikon, Melville, NY). Images were processed by NIS-elements (Nikon).  A 
schematic representation of the process is presented in Fig 2.4. 
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Fig 2.4. Schematic representation of the PKH 26 assay. MCF-7 cells were non-
specifically stained with PKH 26 fluorescence marker prior to tumorspheres culture. 
Spheres were stained with Hoechst 33342 nuclei dye prior to confocal microscopy 
analysis. 
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Coomassie Plus Protein Assay 
Six Standard solutions (1 mL each) containing 0, 125, 250, 500, 750 and 100 ug/mL BSA 
were prepared. The Coomassie Plus Protein Assay reagent (Thermo Scientific) was 
mixed before use by gently inverting the bottle. 20L of each standard sample were 
mixed with 600L of Coomassie Plus Protein Assay reagent in a cuvette. Samples were 
incubated for 10 minutes at room temperature. Absorbance of all samples was recorded 
by spectrophotometer set at 595nm. Standard curve was constructed by plotting the 
average blank-corrected 595nm reading for each BSA standard vs. its concentration in 
g/mL.  
For experimental samples, lysates were diluted 10-fold in distilled water before they were 
mixed with the Coomassie Plus Protein Assay Regent like the standard solutions. Protein 
concentration of experimental samples was determined according to the standard curve.  
Western immunoblotting 
Tissue or cell lysates (30g per well) were mixed with laemmli buffer (4.4mL of 0.5M 
Tris, pH 6.8; 4.4mL of Glycerol; 2.2mL of 20% SDS; 0.5mL 1% of Bromophenol Blue; 
0.5mL of -mercaptoethanol) and heated @ 95oC for 10 minutes prior to loading on 10% 
SDS-PAGE gels (Bio-rad, Hercules, CA). Gels were run at 100V in the Bio-rad mini-gel 
box system with running buffer (25mM Tris-base, 200mM Glycine, 0.1% SDS, 1L of 
ddH2O, pH 8.3). After the bromophenol blue dye front reaches the bottom of the gel, the 
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gel was then transferred onto Hybond-ECL nitrocellulose membrane in the transfer buffer 
(14.4g glycine, 3.03g Tris base, 200mL of methanol, 1L of ddH2O) at 16-Watt for 2 
hours. Non-specific binding sites were blocked by TBST (30mL of 5M NaCl, 10mL of 
1M Tris-HCl, pH 7.4, 0.5mL of Tween-20) containing 5% non-fat powder milk in TBST 
for 1 hour, and incubated overnight at 4
o
C with anti-pAKT antibodies (4060S; Cell 
Signaling, Danvers, MA) diluted at 1:1000, anti-pERK (sc-7383; Santa Cruz 
Biotechnology, Santa Cruz, CA) diluted at 1:1000, anti-PRLR (H300) (sc-20992; Santa 
Cruz Biotechnology) or anti--actin (A1978; Sigma) diluted at 1:10000. Next the 
membranes were washed 3 times with TBST and incubated for 1 hour with HRP-
conjugated goat anti-rabbit IgG or goat anti-mouse IgG secondary antibodies (Bio-rad) 
diluted at 1:2000. Western blot signals were detected by using ECL Western Blotting 
Substrate (GE Healthcare, Piscataway, NJ) and detected by CCD camera (Protein Simple, 
Santa Clara, CA).  
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Mice Housing 
Breeding pairs of FVB/N-Tg (MMTVneu) 202Mul/J mice, expressing the wild-type rat 
neu transgene under the control of the mouse mammary tumor promoter (MMTV-neu) 
and BALB/cByJ were obtained from The Jackson Laboratory (Bar Harbor, ME). The 
colony was expanded and housed in the accordance with The Guide for the Care and Use 
of Laboratory Animals. All animal studies were reviewed and approved by the Clemson 
University Institutional Animal Care and Use Committee.  
Tumorgenicity experiments 
Tumorigenicity was evaluated by pre-treatment of MCneuA and 4T1 cells in vitro and 
subsequently inoculated subcutaneously into 12 weeks old neu transgenic mice. MCneuA 
cells were harvested at 80% confluency and subsequently seeded in T-150 (Corning) 
flasks at 1x10
6
 cells per flask. MCneuA cells were treated with either (1) 2g/mL 
cisplatin, (2) 100ng PRL and 2g/mL cisplatin, or (3) left alone as control for 3 days in 
DMEM supplemented with 5% FBS. 4T1 cells were treated with either (1) 100ng/mL 
PRL, (2) 150ng/mL cisplatin, (3) 100ng/mL PRL and 150ng/mL cisplatin, or (4) left 
alone as control for 3 days in DMEM supplemented with 5% FBS. Treated cells were 
harvested and were subsequently injected into mammary fat pads through the skin of neu 
transgenic mice, with cisplatin treated cells on the left side and PRL and cisplatin 
combination treated cells on the right side of the mouse. Each injection site  consisted of 
100L (5x105 cells) volume of matrigel (356231; BD Biosciences, San Jose, CA) mixed 
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with PBS, at the radio of 1:1. Tumor growth was measured twice weekly, and tumor 
volume is calculated by (width
2
)*(length/2).  
Preparation of Tumor and Cell Lysates 
Tumors were minced with a sterile scalpel and washed in 5mL PBS, pH 7.4. Tissues were 
minced into paste with a sterile scalpel before being washed three times in 5mL PBS. The 
paste was then re-suspended in lysis buffer (50mM Tris-HCl, pH 7.4; 1% NP-40; 0.25% 
sodium deoxycholate; 150mMK NaCl; 1mM EDTA, pH 8.0; 1 g/mL aprotinin; 1 
g/mL leupeptin; 1 g/mL pepstatin A; 170 g/mL PMSF; 180 g/mL Na3VO4; 50mM 
NaF) and homogenized using an electric homogenizer (250mg tumor tissue per 1mL lysis 
buffer).  
For cell lysates, cells were harvested by using 0.4% trypsin-EDTA (Invitrogen) and 
washed with PBS three times prior to re-suspending cells in 100L of lysis buffer. Either 
tumor or cell lysates were transferred then into microcentrifuge tubes, places on ice for 
15 minutes and centrifuged at 12,000g for 15 minutes at 4
o
C. Supernantant were 
collected and the protein content was determined using Coomassie Plus Protein Assay 
reagent and BSA standards (Thermo Scientific, Rockford, IL).  
MMTV/neu mammary tumor treatment experiments 
The animals used in the in vivo treatment were MMTV/neu mice that developed neu 
breast carcinoma reached approximately 1 cm diameter at 6 months of age. Mice were 
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randomly selected into three groups. They were treated with intraperitoneal injection of 
either (1) 5mg/kg/week cisplatin, (2) 50g PRL daily and 5mg/kg/week cisplatin, or (3) 
left alone as a control for 31 days. Tumor size was measured weekly, and tumor volume 
is calculated by (width
2
)*(length/2). At the end of the course of the treatment, tumors 
were removed from mice, minced into paste and enzymatically dissociated in 10mL of 
0.4% trypsin for 10 minutes at 37
o
C. After the 10 minutes incubation, 30mL of PBS was 
added and the tube was inverted several times. Cell suspensions were then filtered 
through 40m strainer and re-suspended in 1mL of PBS. Cells derived from different 
tumors were inoculated into mammary fat pads of 12 weeks old neu transgenic mice with 
cells derived from the cisplatin treated tumor on the left side and combination treated 
tumor on the right side. Each injection site is consisted of 100L (5x105 cells) volume of 
matrigel (BD Biosciences) mixed with PBS, at the ratio of 1:1. The outgrowth of tumors 
was observed weekly up to three weeks.  
Breast cancer metastasis model 
Mouse breast cancer 4T1 cells were harvested at 80% confluency. Cells were washed 
with 10mL of PBS three times and eventually re-suspended in the appropriate amount of 
PBS prior to mixing with matrigel (BD Biosciences) at the ratio of 1:1. In this study, 12 
weeks old BALB/cByJ mice were used. Each mouse received 100L (5x105cells/mouse) 
of cells intravenously.  Mice were randomly divided into three treatment groups, (1) 
5mg/kg of cisplatin twice a week, or (2) in combination with 50g PRL for the first week 
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and 100g PRL for the remaining course of treatment, or (3) left alone as control. Mice 
were observed once every day for its survival.  
Statistical Analyses 
All statistical analyses were performed using GraphPad Prism version 5.01 for Windows 
(GraphPad Software, La Jolla, CA). Results are presented as the mean±s.e.m. and were 
analyzed using Student t test unless otherwise specified. Statistical Analyses for 
concentration response curve was based on the values of the top, bottom and EC50 or IC50. 
p<0.05 was considered statistically significant.  
  
64 
 
CHAPTER THREE 
RESULTS 
 
Mixed effects of PRL in human and mouse cell lines under differentiating culture 
We first performed the proliferation assay to examine if PRL may enhance cell sensitivity 
to chemotherapeutics. We have chosen two breast cancer cell lines, SKBR3 (Human, 
HER2) and MCneuA (Mouse). Cells were cultured and treated in the presence of 5% 
FBS in an anchorage dependent manner. Our results demonstrated the IC50 of doxorubicin 
and its combination with PRL are 68.84±1.53 ng/mL and 150±1.43ng/mL respectively in 
SKBR3 cells (Fig 3.1).  The IC50 of cisplatin and its combination with PRL are 
2.46±0.135g/mL and 3.81±0.121g/mL respectively. The addition of PRL promotes 4% 
increase of proliferation at low dose of doxorubicin (4ng/mL) but promotes 71% increase 
at maximum dose of doxorubicin (1000ng/mL). In contrast, the addition of PRL promotes 
~6-8% proliferation in the full range of cisplatin consistently. It is important to note that 
there is no statistical significance difference of IC50, maximum and minimum response 
between either doxorubicin or cisplatin and its corresponding combination with PRL in 
SKBR3 cells.  
We have also examined the effects of PRL in MCneuA cells. In contrast to SKBR3 cells, 
the addition of PRL has significantly increased IC50 of doxorubicin from 
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63.66±1.61ng/mL to 371.3±1.84ng/mL (Fig 3.2). However, when we compared the IC50 
of cisplatin with or without PRL, there is no statistical significance. The IC50 of cisplatin 
with or without PRL combination is 1.63±0.132g/mL and 1.74±0.124g/mL, 
respectively. Addition of PRL to doxorubicin resulted in a marginal 1% decrease of 
proliferation at low dose of doxorubicin (4ng/mL) but resulted in 20% decrease at high 
dose of doxorubicin (1000ng/mL) (Fig 3.2). In contrast, the addition of PRL to low doses 
of cisplatin (125ng/mL) resulted in 4% increase of proliferation and 25% increase at high 
dose of cisplatin (40g/mL) (Fig 3.2). However, statistical analysis revealed that there is 
no statistical significant difference of IC50, maximum or minimum values between 
cisplatin and its combination treatment with PRL.  
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Fig 3.1 Growth response of SKBR3 cells to cisplatin or doxorubicin, or combination 
treatments. Top) Cells were given concentration dependent dose of doxorubicin (4ng/mL 
to 1000ng/mL) or combination with fixed dose of PRL (100ng/mL) for 72 hours. Bottom) 
Cells were given concentration dependent dose of cisplatin (0.125g/mL to 40g/mL) or 
combination with fixed dose of PRL (100ng/mL) for 72 hours. There was no statistical 
significance of IC50 between doxorubicin or cisplatin to its corresponding combination. 
After continuous exposure to treatment, MT-PMS colorimetric growth assay was 
performed. Results were expressed as a percentage of control (cells with no treatment) in 
each experiments. All data represent mean ± s.e.m. of three independent experiments.  
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Fig 3.2 Growth response of MCneuA cells to cisplatin or doxorubicin, or combination 
treatments. Top) Cells were given concentration dependent dose of doxorubicin 
(1.25ng/mL to 1000ng/mL) or combination with fixed dose of PRL (100ng/mL) for 72 
hours. Bottom) Cells were given concentration dependent dose of cisplatin (0.125g/mL 
to 40g/mL) or combination with fixed dose of PRL (100ng/mL) for 72 hours. After 
continuous exposure to treatment, MT-PMS colorimetric growth assay was performed. 
Combination treatment with doxorubicin resulted in an increase of IC50 from 
63.66±0.21ng/mL to 371.3±0.27ng/mL but not in cisplatin combination treatment. 
Results were expressed as a percentage of control (cells with no treatment) in each 
experiments. All data represent mean ± s.e.m. of three independent experiments.  *p<0.05 
of IC50 between doxorubicin and combination treatment.  
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Chemotherapeutic treatments increased BCSCs population, but PRL combination 
wasn’t effective in increasing BCSCs susceptibilities to chemotherapeutics 
Next we tested whether combination of PRL and different chemotherapeutics may reduce 
BCSCs populations. We have tested the combination effects on two breast cancer cell 
lines, T47D (Human), MCneuA (mouse) and primary mammary tumor cells isolated 
from neu transgenic mice. FACS analysis revealed that cisplatin treatment significantly 
increased the ALDH
+
 populations from 37.52±3.05 to 55.8±6.16 (Fig 3.3). There is no 
significant difference of ALDH
+
 populations between control vs PRL, doxorubicin, 
paclitaxel or PRL in combination with the corresponding chemotherapeutics. We have 
also tested ALDH
+
 populations after treatments in T47D cells. Although there is a trend, 
ALDH
+
 populations were increased after doxorubicin and cisplatin treatment; there is no 
statistical difference of ALDH
+
 populations with any chemotherapeutics when compared 
to control, or any chemotherapeutics when compared PRL in addition of its 
corresponding chemotherapeutics in T47D cells (Fig 3.4).  
We have also used different cancer stem cell markers for the identification of BCSCs. We 
have tested the same set of treatment in the same set primary mammary tumor cells 
isolated from neu transgenic mice. Interestingly, our results indicated that primary cells 
responded to doxorubicin and cisplatin treatment when cells are measured by Sca-1 
expression but not PKH26 (Fig 3.5). We also fail to find statistical differences of either 
PKH26
Br
 or Sca-1
+
 cell population between treatments of chemotherapeutics and PRL 
addition to its corresponding chemo.   
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Fig 3.3. FACS analysis of MCneuA cells after treatment of doxorubicin, paclitaxel, 
cisplatin or combination treatment with PRL. Cells were either treated with doxorubicin 
(50ng/mL, red), paclitaxel (7ng/mL, green), cisplatin (2g/mL, blue) or in combination 
with a fixed dose of PRL (100ng/mL) for 72 hours. After treatment, the ALDH assay was 
performed. Cisplatin treated cells resulted in an increase of ALDH
+
 cell population from 
37.52±3.05% to 55.8±6.16%. There is no significant difference between chemo- and 
PRL-chemo combination treatments. Results were expressed as the percentage of ALDH
+
 
cells out of 10,000 cells. All data represent mean ± s.e.m. of four independent 
experiments. Dox, Doxorubicin; Pac, Paclitaxel; Cis, Cisplatin;  *p<0.05 when compared 
to control.  
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Fig 3.4. FACS analysis of T47D cells after treatment of doxorubicin, paclitaxel, cisplatin 
or combination treatment with PRL. Cells were either treated with doxorubicin (50ng/mL, 
red), paclitaxel (7ng/mL, green), cisplatin (2g/mL, blue) or in combination with a fixed 
dose of PRL (100ng/mL) for 72 hours. After treatment, the ALDH assay was performed. 
There was no statistical significant of ALDH
+
 cell population between control and any 
treatments. Results were expressed as the percentage of ALDH
+
 cells out of 10,000 cells. 
All data represent mean ± s.e.m. of four independent experiments.  Dox, Doxorubicin; 
Pac, Paclitaxel; Cis, Cisplatin;   
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Fig 3.5. FACS analysis of primary tumor cells after treatment of doxorubicin, paclitaxel, 
cisplatin or combination treatment with PRL. Cells were either treated with doxorubicin 
(50ng/mL, red), paclitaxel (7ng/mL, green), cisplatin (2g/mL, blue) or in combination 
with a fixed dose of PRL (100ng/mL) for 72 hours. Top)  After treatment, BCSCs were 
measured by PKH 26
br 
cell population. There was no statistical significance of PKH 26
br
 
cell population between control and any treatments. Bottom) After treatment, BCSCs 
were measured by Sca-1
+ 
cell population. Doxorubicin, PRL and doxorubicin 
combination and cisplatin treated cells resulted in 5 to 6-fold increase of Sca-1
+
 cell 
populations. There is no significant difference between chemo- and PRL-chemo 
combination treatments. Results were expressed as the percentage of PKH26
Br
 or Sca-1
+ 
cells out of 10,000 cells. All data represent mean ± s.e.m. of three independent 
experiments. Dox, Doxorubicin; Pac, Paclitaxel; Cis, Cisplatin;   *p<0.05 when 
compared to control.  **p<0.001 when compared to control.  
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Fig 3.6. Confocal microscopic analysis of MCF-7 tumorspheres in A) control, B) 
treatment of PRL (500ng/mL), C) cisplatin (2g/mL), and D) PRL and cisplatin 
combination. Arrows indicated cells retained high density of PKH 26 fluorescence 
marker in control and cisplatin groups. Spheres treated with PRL addition resulted in 
dispersal of PKH 26 fluorescence marker, suggesting PRL treatment induced symmetric 
division of BCSCs. Blue, Hoechst 33342 nuclei fluorescence stain; Red, PKH 26 
fluorescence marker. Original magnification: 400x. Scale bar, 20mm 
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PRL induces symmetric division in BCSCs   
To test the effect of PRL, we first investigated the effect of PRL on BCSC division. 
Confocal microscopy analysis demonstrated that formation of tumorspheres in control or 
cisplatin treatment resulted in minimal dispersal of PKH 26 fluorescence marker, 
indicating asymmetric division of the parental BCSC (Fig 3.6A and 3.6C). The addition 
of PRL resulted in the even distribution of fluorescence (Fig. 3B, 3D) suggesting the 
BCSCs undergo symmetric division in response to PRL stimulation.  
PRL reduces tumorsphere forming ability  
We next examined the effect of PRL on breast cancer cells’ ability to form tumorspheres.   
Treatment with PRL in primary tumorspheres resulted in a 53% reduction of secondary 
tumorsphere formation from 64.27±5.27 to 30.13±4.337 (p<0.01) (Fig 3.7 Top). 
Furthermore, if secondary tumorspheres were treated with PRL and the PRL receptor 
antagonist, G129R, the effect of PRL is reversed in a concentration dependent manner 
(Fig 3.7 Bottom), suggesting the PRL effect is PRL receptor (PRLR) specific.  
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Fig 3.7. PRL reduced tumorspheres forming ability. Top) Ability of tumorspheres 
formation was reduced by 53% as compared to control from cells isolated from primary 
spheres after PRL treatment. Bottom) Secondary tumorspheres formation of MCF-7 cells 
treated with PRL (500ng/mL) or with its antagonist G129R in 5, 10, 20g/mL or with 
G129R alone (20g/mL). Effect of PRL in tumorspheres formation is reversed by adding 
G129R.   
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PRL enhanced cytotoxic effect of cisplatin in tumorsphere assay 
Next we performed the tumorsphere formation assay using different concentrations of 
PRL and cisplatin. We tested the effect of PRL, cisplatin, or combinations of PRL and 
cisplatin on two breast cancer cell lines, MCF-7 (ER+/PR+) and HCC1954 (HER2+). A 
reduction of tumorsphere formation is observed in PRL-treated cultures in a 
concentration dependent manner in both MCF-7 (EC50=202ng/mL) and HCC1954 cells 
(EC50=251ng/mL) (Fig 3.8). The maximum effect of PRL is 500ng/mL in both MCF-7 
and HCC1954 cells. The addition of a fixed dose of cisplatin (2g/mL) enhances the 
response of PRL, resulting lowered EC50=147ng/mL in HCC1954 cells but not in MCF-7 
cells (EC50=210ng/mL). It is important to note that though there is no further 
enhancement of EC50 in MCF-7 cells, the maximum response (tumorspheres count) was 
lowered from 16.89±2.73 to 7.21±3.11 with the addition of cisplatin. 
We next examined the effects of different concentrations of cisplatin while maintaining a 
fixed dose of PRL (500ng/mL). Concentration response experiments showed that the 
addition of PRL significantly reduced the IC50 of cisplatin from 3.56g/mL to 1.03g/mL 
in MCF-7 cells and from 3.75g/mL to 2.05g/mL in HCC1954 cells (Fig 3.9).  
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Fig 3.8. Effect of PRL with fixed dose of cisplatin in tumorspheres formation. 
Concentration response curve of PRL or PRL with fixed dose of cisplatin (2g/mL) in 
secondary tumorspheres formation of Top) MCF-7 cells and Bottom) HCC1954 cells 
respectively. Secondary tumorspheres formation is decreased in a concentration 
dependent manner of PRL treatment. All data represent mean ± s.e.m. of five 
independent experiments. Closed arrow, control; Open arrow, cisplatin   
*, p<0.0001  
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Fig 3.9. Effect of cisplatin with fixed dose of PRL in tumorspheres formation. The 
concentration response curve of cisplatin or cisplatin with fixed dose of PRL (500ng/mL) 
in secondary tumorspheres formation of Top) MCF-7 cells and Bottom) HCC1954 cells 
respectively. IC50 of PRL and cisplatin combination treatment is significantly decreased 
in both MCF-7 and HCC1954 cells. All data represent mean ± s.e.m. of five independent 
experiments. *, p<0.0001  
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PRL and cisplatin combination treatment had no effect in AKT and ERK 
phosphyrlation in vitro in tumorspheres culture 
After we have seen the effects of PRL and cisplatin combinations in reducing 
tumorspheres formation, next we examined whether the addition of PRL may induce 
intracellular signaling cascade. Previous studies have demonstrated that cancer cells 
activate the Akt and MAPK pathways for its survival against chemotherapeutics (Kraus, 
Ferber et al. 2002). Surprisingly, our immunoblotting results indicated that there is no up-
regulation of pAKT and pERK expression with cisplatin treatment in both MCF7 and 
HCC1954 cells (Fig 3.10). Furthermore, combination of PRL and cisplatin treatment did 
not demonstrate any reduction of pAKT and pERK expression when compared to 
cisplatin treatment. Modulation of intracellular signaling cascade of PRL, cisplatin and 
combination treatment was not observed in MCF7 and HCC1954 tumorspheres.  
PRLR isoforms expression is reversed in 2D vs 3D culturing environment 
Immunoblotting results revealed that the balance of long and intermediate forms of PRLR 
expression is reversed in 3D vs 2D culture conditions in both MCF-7 and HCC1954 cells 
(Fig 3.11). Expression of PRLR is higher in 3D culturing conditions than in 2D. 
Furthermore, higher expression of both forms of PRLR was found in MCF-7 cells than in 
HCC1954 cells. This may explain why MCF7 cells have better response to PRL and 
cisplatin combination treatment better than HCC1954 cells.  
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Fig 3.10 Immunoblotting of pAKT and pERK in tumorspheres. Both MCF7 and 
HCC1954 cells were subjected to tumorspheres culture with treatment of PRL 
(500ng/mL), cisplatin (2g/mL) or in combination for 7 days. Top) Immunoblotting of 
pAKT and pERK did not show expression difference between treatments in MCF7 
tumorspheres. Bottom) Immunoblotting of pAKT and pERK did not show expression 
difference between treatments in HCC1954 tumorspheres.  
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Fig 3.11. Immunoblotting of PRLR of MCF-7 and HCC1954 cells. PRLR expression was 
higher in 3D vs 2D culturing conditions. Reversal of LF/IF expression is observed in 3D 
vs 2D. Breast cancer cells T47D served as a positive control, only 2g of total lysate is 
loaded. PRLR, PRL receptor; LF, long form; IF, intermediate form 
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PRL treatment increases tumorigenicity in BALB/c mice but combinations of PRL 
and cisplatin reduce tumorigenicity 
One of the distinct properties of BCSCs is high tumor initiating ability. We examined the 
effects of PRL and cisplatin combination treatment in BALB/c mice. 4T1 cells were pre-
treated in the presence of PRL (100ng/mL), cisplatin (150ng/mL) or in combination of 
PRL and cisplatin. We have tried to test cisplatin dosage in IC50 (2g/mL) and IC25 
(750ng/mL). Cells pre-treated with IC50 and IC25 of cisplatin failed to have tumor 
outgrowth, thus why dosage of cisplatin we decided on this experiments was minimized 
to IC10 (150ng/mL). Our results indicated that pre-treatment of PRL has significantly 
increased tumor growth (Fig 3.12). Combinations of PRL and cisplatin pre-treatment 
resulted in significant delay of tumor outgrowth (Fig 3.12) when compared to control. 
There was no significant difference of tumor size between control and cisplatin pre-
treatment. Furthermore, we failed to observe tumor size difference between pre-treatment 
of cisplatin and combination of PRL and cisplatin.  
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Fig 3.12. Response of 4T1 cells allografts to cisplatin, PRL and cisplatin combination 
treatment. Six animals of each group were given mouse breast cancer cells 4T1. Cells that 
were pre-treated with PRL, cisplatin or PRL and cisplatin combination in vitro for 3 days 
were inoculated into BALB/c mice. Tumor growth curve were plotted for each group 
(control, PRL, cisplatin, PRL+cisplatin). The PRL and cisplatin combination group 
resulted marginal minimal tumor growth.   *p<0.05 when compared to control; **p<0.01 
when compared to control 
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PRL and cisplatin combination treatment reduce tumorigenicity in neu mice by 
suppressing the AKT and MAPK pathways.  
We examined the effects of PRL and cisplatin combination treatment on tumor growth of 
allografts of MCneuA cells. Pre-treatment of both the cisplatin alone group and PRL and 
cisplatin combination group demonstrated a delay of tumor growth when compared to 
control. The PRL and cisplatin combination was the most effective at delaying tumor 
growth (Fig 3.13 and 3.14). The pre-treated MCneuA cells and tumors were analyzed by 
immunoblotting. Western blot analysis revealed that expression of both pAKT and pERK 
was down-regulated in cisplatin or PRL and cisplatin combination pre-treatment in vitro 
(Fig 3.15 Top). It is important to note that PRL and cisplatin combination pre-treatment 
further reduced pAKT expression when compared to cisplatin treatment in vitro. 
Nevertheless, western blot analysis revealed that there is significant increase of 
expression of pAKT and pERK in cisplatin tumors formed by cells treated in vitro prior 
to transplantation (Fig 3.15 Bottom). Conversely, in the PRL and cisplatin combination 
treated tumors pAKT expression was reduced and minimal expression of pERK was 
detected.  
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Fig 3.13. Response of MCneuA cells allografts to cisplatin, PRL and cisplatin 
combination treatment. Six animals of each group were given mouse breast cancer cells 
MCneuA that were pre-treated with cisplatin or PRL and cisplatin combination in vitro 
for 3 days. Tumor growth curves were plotted for each group (control, cisplatin, 
PRL+cisplatin). The PRL and cisplatin combination group resulted minimal tumor 
growth.  *p<0.05 when compared to cisplatin 
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Fig 3.14. Cisplatin treated cells resulted in higher tumorigenicity when compared to PRL 
and cisplatin combination treatment. Six animals of each group were given mouse breast 
cancer cells MCneuA that were pre-treated with cisplatin or PRL and cisplatin 
combination in vitro for 3 days. Tumor growth curve is shown in Fig 3.13. 
Representative tumors are shown here.   
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Fig 3.15. Immunoblotting of pAKT and pERK before and after implantation. Six animals 
of each group were given mouse mammary cancer cells MCNeu A that were pre-treated 
with cisplatin or PRL and cisplatin combination in vitro for 3 days. Top) Immunoblotting 
of pAKT and pERK from MCNeu A cells after treatments in vitro prior to implantation. 
Bottom) Immunoblotting of pAKT and pERK from tumors removed from neu mice. 
Both pAKT and pERK expression are significantly down-regulated in PRL and cisplatin 
combination group when compared to cisplatin group alone. Cis, Cisplatin; PRL, 
prolactin 
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PRL and cisplatin combination treatment inhibits tumor growth and tumorigenicity 
in neu transgenic mice.  
We examined the effectiveness of PRL and cisplatin combination treatment in neu 
transgenic mice that had tumors 0.5cm in diameter. PRL and cisplatin combination 
treated tumors were consistently smaller than cisplatin treated or control tumors after 31 
days (Fig 3.16). Representative tumors were shown in Fig 3.17A. Serial transplantation 
of cells derived from treated tumors revealed that cells isolated from cisplatin treated 
tumors resulted in tumor outgrowth after 21 days (4/4), whereas minimal tumor 
formation was observed from PRL and cisplatin combination treated tumor cells, 
representative samples are shown in Fig 3.17B.  
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Fig 3.16. Growth of natural tumors in MMTV/neu transgenic mice. Mice with tumor 
diameter up to 5mm were assigned randomly into treatment group (control, n=9; cisplatin, 
n=9; PRL and cisplatin, n=10) for 31 days. A) Tumor growth curves were plotted for 
each group (control, cisplatin, PRL+cisplatin). PRL and cisplatin combination group 
showed significant delay of tumor growth. *p<0.05 when compared to cisplatin  
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Fig 3.17. Growth of natural tumors in MMTV/neu transgenic mice. A) Mice with tumor 
diameter up to 5mm were assigned randomly into treatment group (control, n=9; cisplatin, 
n=9; PRL and cisplatin, n=10) for 31 days. Representative tumors of cisplatin and 
combination treatment tumors are shown. B) Tumor outgrowth after tumors were 
enzymatically dissociated and serial transplanted in recipient mice. Tumor outgrowth was 
observed after 21 days at injection sites from cells isolated from cisplatin treated tumors 
(n=4), whereas minimal outgrowth was observed from PRL and cisplatin combination 
treated tumors (n=4).  
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Combination treatment of PRL and Cisplatin treatment prolongs overall survival in 
BALB/c mice.  
Having established the effectiveness of PRL and cisplatin combination treatment in neu 
transgenic mice, we next extended these findings by using the 4T1 metastatic mouse 
mammary cancer model. By using this model, we examined the survival time of the 
BALB/c mice that received a transplantation of tumorigenic 4T1 cells. The median 
survival time of the cisplatin treatment group has been significantly prolonged when 
compared to control (31 days vs 19 days). The addition of PRL to cisplatin treatment 
further extended the median survival time to 34.5 days (Fig 3.18). 
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Fig 3.18. Kaplan-Meier survival curve of cisplatin, PRL and cisplatin combination 
treatment in BALB/c mice. 4T1 cells were intravenously injected into BALB/c mice 
among three treatment groups (Control, n=11; Cisplatin, n=15; PRL and Cisplatin 
combination, n=14). PRL and cisplatin combination group resulted in the longest survival 
of all three groups. Statistical significance was calculated by log-rank test. *p<0.0001 
when compared to control. **p<0.01 when compared to cisplatin treated group.  
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CHAPTER FOUR 
DISCUSSION 
 
There is increasing evidence that breast cancer is driven and maintained by a small 
population of cells that exhibit stem cell properties (Kai, Arima et al. 2010). Resistance 
of BCSCs to cytotoxic chemotherapy remains as one of the major obstacles in successful 
cancer treatment (Abdullah and Chow 2013; Pinto, Widodo et al. 2013). In the current 
study, we have demonstrated the principle of using a stem cell differentiation factor (PRL) 
in combination with a conventional chemotherapeutic (cisplatin), to improve the outcome 
of chemotherapy.  
We first want to examine if PRL may enhance cytotoxic effect of chemotherapeutics in 
proliferation of cells. The maximum, minimum and IC50 from different drug treatments in 
proliferation assay allows us to estimate drug dosage chemotherapeutics for other assays. 
Surprisingly, our results did not demonstrate the effect of PRL enhancing the toxicity of 
chemotherapeutics in proliferation except doxorubicin in MCneuA cells (Fig 3.1 and 3.2). 
The IC50 of PRL and different chemo-combinations was shifted to the right, indicating 
PRL promotes proliferation of cells in the presence of doxorubicin (Fig 3.2 Top). This 
could be due to the fact that the cells we were treating are a heterogeneous population in 
2D culture, thus most cells were differentiated and effects of PRL are only shown in the 
proliferation of the peripheral cells. Our previous lab data has also shown that PRL only 
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has marginal effects (<20% proliferation) on cell proliferation in an adherent culture, 
however, administration of PRL in mice resulted in a significant increase of tumor size 
(Fig 3.12). As we hypothesize PRL may play increase BCSCs susceptibility to 
chemotherapeutics, we speculate the enhanced effects of PRL and cisplatin in terms of 
increasing cell susceptibilities to chemotherapeutics may not be reflected in proliferation 
assay.  
In regards to the proliferation assays that the peripheral differentiated cells may mask the 
effects of PRL, we performed FACS analysis after the treatment of PRL and different 
chemotherapeutics in cell lines and primary mammary tumor cells for the detection of 
BCSCs population. In our study, we have used three different cancer stem cell markers 
for the detection of BCSCs, ALDH
+ 
(intracellular), PKH26
Br
 (cell membrane) and Sca-1
+
 
(extracellular). Previous studies have demonstrated that cells with high expression of 
aldehyde dehydrogenase (ALDH) exhibited BCSCs characteristics (Charafe-Jauffret, 
Ginestier et al. 2009). Our FACS results demonstrated that ALDH
+
 population of BCSCs 
were increased with the treatment only by cisplatin in MCneuA cells (Fig 3.3). There is 
no significant increase of ALDH
+
 cell population by the treatment of doxorubicin or 
paclitaxel. Furthermore, PRL and cisplatin treatment failed to have reduction of ALDH
+
 
when compared to any of its corresponding chemotherapeutics combinations (Fig 3.3 and 
3.4). Taken together, our data indicates that though ALDH
+ 
cell population may be 
representative for BCSCs population, effective treatment of chemotherapeutics or in 
combination with PRL may not be reflected by ALDH.  
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As we speculate ALDH may not reflect effects of PRL and chemotherapeutics 
combination treatment, we have tried two other cancer stem cell markers, PKH26 and 
Sca-1. Previous studies have reported that PKH26 is a fluorescence marker that non-
specifically binds on cell membrane. The fluorescence dye may diffuse un-evenly into 
daughter cells due to the nature of asymmetric division of BCSCs (Cicalese, Bonizzi et al. 
2009). Our results revealed that there is no significant increase or reduction of 
PKH26
Bright 
cells with the treatment of PRL, or any chemotherapeutics, or in any 
combination with PRL (Fig 3.5 Top). Interestingly we observed significant increase of 
BCSCs by the marker Sca-1 with the treatment of doxorubicin (Fig 3.5 Bottom). Our 
primary mammary tumor cell responses suggested that different cancer stem cell markers 
with the same treatment may result in different BCSCs population and responses. We 
speculate that the increase of BCSCs with chemotherapeutics treatment wasn’t observed 
in cell lines because cell lines were cultured in anchorage dependent environment (Dey-
Guha, Wolfer et al. 2011). As BCSCs were not dividing actively in media with 
differentiation agents (such as FBS), PKH26 fluorescence markers may not reflect the 
drug response in such cell population. Moreover, consistent increase of BCSCs in 
doxorubicin and cisplatin from primary tumor cells when compared to cell lines also 
suggested that the heterogeneity of tumors may contribute the drug treatment effects. 
It is important to note that FACS analysis did not provide insights on whether the 
increase of BCSCs population was due to chemotherapeutics killing peripheral cells, thus 
enriching the BCSCs population; or cells were transforming into BCSCs due to the 
therapeutic drug pressure. Furthermore, combination of PRL and cisplatin treatment only 
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marginally reduced BCSCs populations in cell lines. Taken together, FACS analysis of 
multiple BCSCs markers, including extracellular, membrane or intracellular markers, did 
not provide strong evidence that a combination of PRL and cisplatin treatment reduces 
BCSCs population significantly.   
Reports have suggested that BCSCs may be measured by either BCSC markers or 
tumorspheres assay (Charafe-Jauffret, Ginestier et al. 2009). The tumorspheres assay 
allows culturing conditions favorable to  proliferation of BCSCs and early progenitor 
cells. In theory, each sphere is originated from one BCSC. Recent studies have also 
shown that tumorspheres resemble the heterogeneity of early tumor transformation (Liu, 
Deng et al. 2007; Nolte, Venugopal et al. 2013). In this regard, we combined the 
tumorspheres assay and the PKH 26 assay to examine whether PRL may have effects on 
BCSCs. Our results demonstrated that PRL modulates BCSC cell division pattern (Fig 
3.6).  Cicalese et al. reported that staining cells with PKH 26 fluorescence marker prior to 
culture in tumorsphere-forming conditions, one may identify the parental BCSC in a 
tumorsphere (Cicalese, Bonizzi et al. 2009). The data presented in Figure 3.6 revealed 
that, in most cases, after exposure to PRL treatment BCSCs did not undergo typical 
asymmetric division, evidenced by dispersed PKH 26 fluorescence marker throughout 
tumorspheres (Fig 3.6B and 3.6D). In contrast, minimal dispersal of the PKH 26 
fluorescence marker is observed in control and cisplatin treated groups (Fig 3.6A and 
3.6C), suggesting the small subsets of cells with high density of PKH 26 are the BCSCs 
which maintained self-renewal ability. To further confirm the effect of PRL on BCSCs, 
we compared the ability of tumorsphere formation from cells isolated from primary 
96 
 
spheres with or without PRL treatment. We were able to demonstrate that cells isolated 
from spheres after PRL treatment formed fewer tumorspheres in the subsequent passage 
(Fig 3.7Top). These data indicate that the addition of PRL modulated BCSCs division 
pattern and decreased the potential of tumorsphere formation. 
We then examined whether the effect of PRL modulating cell division pattern may affect 
the self-renewal ability of BCSCs. We found that cultivation of primary spheres without 
treatment, and subsequent dissociation of primary spheres into single cells and 
application of PRL treatment in secondary tumorspheres formation would allow a more 
profound PRL effect. Our results revealed that BCSCs respond to PRL treatment in a 
concentration dependent manner (Fig 3.8). We have also demonstrated that the effect of 
PRL on BCSC was mediated through PRLR as this effect could be reversed through an 
addition of a PRL receptor antagonist, G129R (Fig 3.7Bottom). Previous reports have 
demonstrated that tumorspheres are formed by cells with self-renewal potential (Singh, 
Clarke et al. 2003; Bulstrode, Jones et al. 2012). The reduction of tumorsphere formation 
in a PRL concentration dependent manner strongly suggested that PRL treatment reduced 
the self-renewal ability of BCSCs. 
Having established the effect of PRL on BCSCs, we then investigated whether PRL could 
improve chemotherapeutic outcome.  We were able to demonstrate that when cells were 
treated with cisplatin alone, the number of tumorspheres is marginally lower compared to 
control (Fig 3.8, indicated by arrows: closed arrow, control; open arrow, cisplatin), which 
agrees with previous findings that BCSCs are resistant to chemotherapeutics (Pinto, 
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Widodo et al. 2013). When cisplatin treatment was combined with PRL, the tumorsphere 
count was decreased in a concentration dependent manner (Fig 3.8). In agreement with 
this experiment, we have found that PRL (500 ng/mL) significantly lowered the IC50 of 
cisplatin in both MCF-7 and HCC1954 cells (Fig 3.9). These results demonstrated that 
the addition of PRL enhanced the effect of cisplatin measured either by reducing total 
tumorsphere count or by lowering the IC50 value.  
We have also examined whether PRL and cisplatin treatments modulate intracellular 
signaling cascade. As we have demonstrated that PRL plays a role in reducing 
tumorspheres formation ability via PRLR, we then examined the canonical PRL pathway 
via the Akt and MAPK pathway. Surprisingly, our results have demonstrated that 
phosphorylation of Akt and ERK in tumorspheres was not modulated by PRL, cisplatin, 
or PRL and cisplatin combination (Fig 3.10).  
It is interesting to note that MCF-7 cells have higher PRLR levels than HCC1954 cells 
(Fig 3.11) in both 2D and 3D cultures, which may explain why MCF-7 cells have the 
better response to PRL treatment.  Furthermore, PRLR expression was higher in 
tumorspheres (3D) than in adherent (2D) cell culture conditions, the balance of the 
functional long isoform and non-functional intermediate isoform is reversed in 2D vs 3D 
(Fig 3.11). The functional role of this imbalanced long and intermediate isoforms of 
PRLR remains to be investigated.  
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Taken together in our in vitro assays, we have concluded that PRL treatment induced 
symmetric division of BCSCs. Such changes of division pattern may be a factor 
contributing in reducing BCSCs tumorspheres formation abilities. Furthermore, reduction 
of tumorspheres formation abilities by PRL has increased cells susceptibility to cisplatin 
and thus enhanced the outcome of cisplatin treatment. Though we have demonstrated that 
the action of PRL is via PRLR, however, we failed to demonstrate PRL modulating the 
canonical PRL intracellular signaling cascade. Mechanisms of PRL effects in BCSCs 
remain to be investigated. 
To further test our hypothesis that PRL may enhance the therapeutic outcome of cisplatin, 
we used in vivo assays.  Our first experiment was testing whether a PRL and cisplatin 
combination treatment may reduce tumorigenicity. We have tried two different mouse 
cell lines to test the effects of PRL and cisplatin treatment. Our results showed that pre-
treatment of 4T1 cells with cisplatin did not significantly delay tumor growth (Fig 3.12). 
This could be because the dose of cisplatin we use is only at IC10. Our previous 
experiments (data not shown) failed to initiate tumors if we used the cisplatin dose at IC25 
or IC50. Our data has shown that PRL pre-treatment significantly promotes tumor growth 
but not in combination with cisplatin (Fig 3.12). Though there is no statistical significant 
difference of tumor volume between pre-treatment of cisplatin and combination with 
PRL, the reverse effects of PRL with or without cisplatin suggested that the effects of 
combination may be observed if the dose of cisplatin can be increased with a less 
aggressive breast cancer cell line.  
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Next we tested the combination treatment effects in MCneuA cells. The dose of cisplatin 
in this cell line was at IC50. Our results showed that pre-treatment of MCneuA cells with 
cisplatin and low-dose of PRL treatment delayed tumor growth 25 days after tumor 
inoculation (Fig 3.13 and 3.14). Samples from the induced tumors revealed that strong 
activation of Akt and ERK were observed in cisplatin treated tumors (Fig 3.15Bottom), in 
contrast to downregulation of Akt and ERK in vitro (Fig 3.15Top). Furthermore, 
reduction of Akt and ERK phosphorylation was observed in PRL and cisplatin 
combination treated tumors when compared to cisplatin treated group alone, moreover, 
expression level of ERK was restored to control tumor level (Fig 3.15Bottom). The Akt 
and MAPK pathways have been reported to play central roles in chemoresistance (Kim, 
Dan et al. 2005; Chung, Tang et al. 2012). Overexpression of Akt and ERK is 
consistently observed in clinical samples that exhibit chemoresistance (Oki, Baba et al. 
2005; Chung, Tang et al. 2012). Our results suggest that PRL and cisplatin treatment 
reversed the Akt and ERK signaling cascade, which may be a contributing factor for the 
delay of tumor growth.  Compared to our immunoblotting results in vitro, modulation of 
signaling cascade in tumors suggested that the effects of PRL may be involved in tumor 
microenvironment rather than the nutrient deficient culturing environment like the 
tumorspheres culturing conditions.  
Moreover, delay of tumor growth was observed in MCneuA cells but not in 4T1 cells 
when compared to cisplatin alone, this could be due to the aggressiveness of 4T1 cells. 
As 4T1 cells are highly metastatic and tumorigenic, optimal balance of cisplatin and PRL 
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is not found, suggesting the PRL and cisplatin combination treatments may be more 
suitable for breast cancers that are less aggressive and receptor status associated.  
In addition to the transplantation model, we also examined mammary tumor growth after 
treatment with PRL and cisplatin in neu transgenic mice. Our results showed that 
continuous intraperitoneal administration of PRL and cisplatin significantly delayed 
tumor growth (Fig 3.16). Furthermore, we enzymatically dissociated treated tumors into 
single cells and inoculated into recipient mice side by side to observe the tumorigenicity 
of cells derived from tumors with different treatments. Cells derived from PRL and 
cisplatin treated tumors resulted in minimal tumor outgrowth whereas tumor formation 
was observed by cells derived from cisplatin treated tumor (Fig 3.17B), suggesting the 
addition of PRL treatment may have induced differentiation of BCSCs in the parental 
tumors, thus increasing the BCSCs susceptibilities to cisplatin and causing minimal 
outgrowth in secondary tumors.  
Having established the effectiveness of PRL and cisplatin combination treatment in 
tumor growth, we extended these findings by using the highly metastatic 4T1 mouse 
mammary cancer model and evaluate the survival time. Our results showed that cisplatin 
treatment significantly increased the survival time by 12 days compared to the control 
group. PRL and cisplatin treatment further increased the survival time by 3.5 days (Fig 
3.18).   
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In summary, the data we presented showed that addition of PRL to cisplatin treatment in 
breast cancer cells reduced their ability to form tumorspheres, suggesting that PRL may 
increase the BCSCs susceptibilities to cisplatin. We further demonstrated that PRL and 
cisplatin combination treatment delayed tumor growth and reduced tumorigenicity in 
mice. Overall, these findings proved in principle that the addition of a differentiation 
factor (PRL) to conventional chemotherapeutics treatment (cisplatin) may be an 
alternative method to target BCSCs.   
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CHAPTER FIVE 
CONCLUSIONS 
 
It has been well documented that CSCs are resistant to radiation and chemotherapy and 
capable of tumor initiation (Ahmed, Abubaker et al. 2010; Siddique and Saleem 2012). In 
this study, we have presented data that showed addition of PRL to cisplatin reduced the 
growth of BCSCs in vitro, possibly by inducing cell differentiation, thus increasing 
BCSCs susceptibilities to cisplatin. We have also provided evidence that PRL and 
cisplatin combination treatments delayed tumor growth and reduced tumorigenicity by 
downregulating the Akt and MAPK signaling cascade. Overall, these findings have 
provided evidence that the addition of PRL to cisplatin treatments may be a potential 
alternative approach in targeting BCSCs and treating breast cancer.  
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